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ABSTRACT 
Human immunodeficiency virus (HIV) is the virus causing acquired immune deficiency 
syndrome (AIDS). Since the discovery of HIV/AIDS over three decades ago, this disease has 
claimed millions of lives. One of the major accomplishments of modern history came in 
1996, when combination antiretroviral therapy (cART) was introduced. Treatment with 
cART caused the death rates from AIDS to decrease dramatically. Although current cART is 
effective in suppressing HIV type 1 (HIV-1) it is not curative and therefore meticulous life-
long therapy is necessary. To effectively target HIV-1 persistence with the goal of achieving 
a cure, it will be important to determine the source and dynamics of persistent viremia. In the 
work presented in this thesis we compare the different approaches for measuring the 
persistent HIV-1 reservoir. We also use highly sensitive assays to genetically characterize 
intracellular HIV-1 within a broad spectrum of cells sorted from unique tissue samples from 
patients on long-term suppressive cART. 
In paper I we compare eleven different approaches for quantifying persistent HIV-1. Results 
from this study showed major differences among the assays. The viral outgrowth assay, 
which is a culture-based assay that quantifies replication competent virus, resulted in 
measurements of replication competent virus that were at least 300-fold lower compared to 
PCR-based methods which measured total and/or integrated HIV-1 DNA. The differences 
between these methods may reflect the number of defective viral genomes in cells. Overall, 
the study reveals many difficulties in measuring the latent reservoir and shows that there is 
currently no assay that will accurately measure the latent reservoir during clinical trials of 
curative strategies.  
In papers II-IV we genetically characterized intracellular HIV-1 DNA within a broad 
spectrum of cells sorted from different anatomical compartments of eight patients on long-
term cART. In paper II we investigated whether CD34
+
 hematopoietic progenitor cells 
(HPCs) from the bone marrow serve as an HIV-1 reservoir. In this study we did not detect 
HIV-1 DNA in CD34
+ 
HPCs indicating that this cell type is not a source of persistent HIV-1. 
In papers III and IV we genetically characterized intracellular HIV-1 in different cell types 
from peripheral blood, gut-associated lymphoid tissue (GALT) and lymph node tissue. We 
found that the majority of HIV-1 DNA was detected in memory CD4
+
 T cells and that 
participants who initiate therapy during early infection have a lower intracellular HIV-1 
infection frequency. These results imply that despite several years of therapy, memory CD4
+
 
T cells serve as an important reservoir and that early initiation of therapy results in a smaller 
latent reservoir. In paper III we used phylogenetic analyses to study the genetic evolution of 
HIV-1 between samples isolated before initiation of therapy and several years after 
suppressive therapy. Our studies revealed a lack of substantial HIV-1 genetic evolution 
during cART which strongly suggests that ongoing replication is not a major cause of viral 
persistence in memory T cells. 
In paper IV we evaluated the longitudinal stability of the HIV-1 reservoir and the role of 
cellular proliferation in maintaining persistent HIV-1 during cART. Our results show that 
memory T cells retained a relatively constant HIV-1 DNA integrant pool that was genetically 
stable during long-term cART. These DNA integrants appear to be maintained by cellular 
proliferation and longevity of infected cells, rather than by ongoing viral replication. 
In conclusion, the work presented in this thesis has helped us to gain a fuller appreciation for 
the range of cells and tissues containing HIV-1 DNA in patients on long-term cART and a 
better understanding as to how intracellular HIV-1 DNA is maintained in different tissues. 
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1 AIMS 
The general aim of this thesis was to characterize HIV-1 populations in patients on long-term 
suppressive therapy. More specifically, the objectives of this thesis were: 
PAPER I: To compare different methods used to measure the viral reservoir during 
eradication studies.   
PAPER II: To investigate whether hematopoietic progenitor cells from bone marrow tissue 
are an important viral reservoir in patients on effective therapy. 
PAPER III: To genetically characterize HIV-1 DNA within T cell subsets sorted from 
peripheral blood and gut-associated lymphoid tissue in patients on effective 
therapy and to explore whether this reservoir is replenished by residual HIV-1 
replication.  
PAPER IV: To define the stability of the intracellular HIV-1 DNA pool during effective 
antiretroviral therapy and to explore the role of T cell proliferation as a cause of 
HIV-1 persistence. 
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2 THE HUMAN IMMUNODEFICIENCY VIRUS 
2.1 THE HIV PANDEMIC 
2.1.1 The Discovery of HIV 
Over three decades have passed since acquired immune deficiency syndrome (AIDS) was 
recognized as a new disease. The first documentation of AIDS  was in 1981 when previously 
healthy young homosexual men from Los Angeles and New York were treated for 
opportunistic diseases such as Kaposi’s sarcoma and Pneumocystis carinii pneumonia [1-3]. 
Subsequently,  several similar cases were reported throughout the United States and the first 
AIDS cases were documented in other countries [4-7]. At this time, the disease did not have a 
name and the cause was unknown. Organizations referred to the disease in different ways e.g. 
lymphadenopathy (swollen glands), Kaposi’s sarcoma and Opportunistic Infections (KSOI), 
gay-related immune deficiency (GRID) or “gay-cancer” [8-11]. In December 1982, a child 
who received a blood transfusion died of an AIDS related infection. This was the first clear 
evidence that the disease was caused by an infectious agent [12]. The causative agent, now 
known as human immunodeficiency virus (HIV), was subsequently identified in 1983 by 
doctors at the Pasteur Institute in France [13]. Drs. Francoise Barré-Sinoussi and Luc 
Montagnier were awarded the Noble Prize for their finding in 2008. 
2.1.2 The Origin and Classification 
The origin of HIV has been traced to the simian immunodeficiency viruses (SIV) naturally 
infecting African primates. The SIV variants were introduced to humans through several 
independent cross-species transmissions, with each successful zoonotic transmission resulting 
in different lineages of HIV [14, 15]. HIV is divided into HIV type 1 (HIV-1) groups M, N, O 
and P and HIV type 2 (HIV-2) groups A-H. HIV-1 originates from SIVcpz found in the 
West-Central African chimpanzees and probably also from SIVgor found in western gorillas 
[16], whereas HIV-2 has been linked to the transmission of SIVsmm found in sooty 
mangabeys [17, 18]. HIV-1 is more infectious and causes a faster progression to AIDS 
compared to HIV-2 [19, 20]. HIV-1 group M is responsible for over 95% of infections 
worldwide and can be further divided into nine subtypes (A, B, C, D, F, G, H, J and K) and 
many circulating recombinant forms (CRFs) [21]. Subtype C is the most prevalent subtype 
world-wide whereas subtype B is the most dominant subtype in Europe, the United States, 
and Australia  [22]. As a result, most research has been done on HIV-1 subtype B, including 
the studies conducted for this thesis. 
2.1.3 The Global Situation of HIV/AIDS 
In the last 15 years alone, around 38 million people have become infected by HIV and the 
disease has claimed more than 25 million lives. In 2014 approximately 37 million people 
globally were living with HIV (Figure 1). The prevalence of the disease varies greatly 
between regions with Sub-Saharan Africa being the most severely affected region accounting 
for about 70% of all HIV-infected individuals. Fortunately, the number of newly infected 
individuals is declining in most parts of the world, but infection rates are  still high. During 
2014, 2 million individuals became newly infected worldwide. This is a great reduction from 
2000, when 3.1 million people became newly infected [23].  
 
 
 
    
 
 
 
Figure 1. Adults and children estimated to be living with HIV globally in 2014. Data from 
UNAIDS 2014 Global Statistics. 
2.2 HIV-1 VIROLOGY 
2.2.1 The HIV Virion 
2.2.1.1 Structure 
HIV-1 and HIV-2 are members of the Lentivirus genus of the Retroviridae family. The HIV-1 
particle is approximately 120 nm in diameter and roughly spherical. Similar to other 
lentiviruses, HIV is enveloped by an outer lipid bilayer derived from the host cell membrane. 
Trimers of the viral envelope surface glycoprotein (SU, gp120) are anchored to the virus via 
interactions with the envelope transmembrane protein (TM, gp41). Lining the inner surface of 
the viral membrane is the matrix (MA, p17). A cone-shaped capsid formed by the capsid 
protein (CA, p24) surrounds the viral genome, which forms a stable complex with the 
nucleocapsid protein (NC, p7). The nucleic acid consists of two copies of non-covalently 
linked, positive-sense single-stranded RNA (+ssRNA) molecules. The capsid also contains 
the three viral enzymes that are essential for replication: reverse transcriptase (RT, p66/p51), 
protease (PR, p10) and integrase (IN, p32). HIV has evolved a variety of regulatory and 
accessory proteins that modulate the replication cycle and the host immune responses. 
Packaged in the HIV-1 particles are the accessory proteins Nef (p27), Vif (p23) and Vpr 
(p15). Additional viral proteins that function in the host cell are Rev (p19), Tat (p14) and Vpu 
(p16), however, these are not present in the virion [24] (Figure 2). 
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Figure 2. Schematic structure of the HIV-1 virion and the genomic organization. 
2.2.1.2 Genomic Organization 
The genomic size of HIV is approximately 10 kilobases (kb) containing open reading frames 
encoding for several viral proteins. The three major structural genes, common for all 
retroviruses, are group specific antigens (gag), polymerase (pol) and envelope (env). The 
primary transcript of HIV-1 is a full-length mRNA, which is subsequently translated into the 
Pol and Gag proteins. The pol-gene is highly conserved and encodes the viral enzymes RT, 
PR and IN. These enzymes are essential for transcription, integration and proteolytic 
processing of viral proteins. Initially the viral enzymes are produced as a Pol precursor 
polyprotein and auto-cleaved by the PR region into enzyme products. The gag-gene encodes 
four proteins needed for the structural elements. The precursor protein is post-translationally 
cleaved and modified by the viral protease into capsid protein, matrix protein, nucleocapsid 
protein and a protein having a role in budding (p6). The env-gene encodes the envelope 
glycoproteins that are essential for recognition, binding and entry into target cells as it 
contains the binding sites for the CD4 receptor as well as co-receptors. The precursor gp160 
is proteolytically cleaved by cellular proteases into gp120 and gp41. The surface of gp120 has 
five variable loops (V1-V5), which are carbohydrate rich. In addition to the major structural 
genes, HIV-1 has two regulatory genes (tat and rev) and four accessory genes (vif, vpr, vpu 
and nef), which are important for regulation of the viral life cycle and immune evasion [24] 
(Figure 2). 
2.2.2 Replication 
Similar to other retroviruses the HIV-1 replication cycle involves reverse transcription of the 
RNA viral genome to form double-stranded DNA. The viral DNA can subsequently be 
integrated stably into the chromosomal DNA resulting in the provirus. 
2.2.2.1 Binding and Entry 
The initial step in the HIV-1 replication cycle is a high-affinity binding of the surface 
glycoprotein gp120 to the cellular receptor CD4. The binding results in conformational 
changes in gp120 leading to exposure of new epitopes thereby allowing binding to the co-
receptor CC chemokine receptor 5 (CCR5) and/or CXC chemokine receptor 4 (CXCR4). 
Thereafter a second conformational change occurs in gp120, which triggers the fusion 
peptide in gp41 to penetrate the cell membrane. Consequently, the virion and the host cell 
    
membrane are brought close together, allowing fusion of the membranes and the capsid can 
be released into the cytoplasm [25, 26].  
2.2.2.2 Reverse Transcription 
Following the release of the capsid, the viral RT enzyme directs the synthesis of a linear 
double-stranded DNA (dsDNA) copy from the +ssRNA genome. This complex process, 
called reverse transcription, is performed inside a partially opened capsid. The process is 
primed by a human transfer RNA (tRNA) that is bound to the 5´ end of the RNA genome. 
During reverse transcription the RT enzyme jumps between the two +ssRNA templates [27]. 
If the two templates are genetically distinct this leads to a new recombinant virus. 
Recombination significantly contributes to HIV genetic variation and evolution (see section 
2.3.1). The RT enzyme contains a DNA polymerase domain and a ribonuclease H (RNAse 
H) domain. The RNAse H activity degrades the RNA template immediately after its 
transcription to the first complementary DNA strand, which then serves as template for the 
synthesis of the second DNA strand. During the formation of dsDNA, long terminal repeats 
(LTRs) are generated in the 5´and the 3´ ends of the genome, which are necessary for 
subsequent integration and transcription. 
2.2.2.3 Integration 
The dsDNA forms a pre-integration complex (PIC) together with the viral enzyme integrase 
(IN), p17 and Vpr. The PIC is actively transported from the cytoplasm to the nucleus. Here 
the IN catalyzes integration of the full-length dsDNA into the host chromosome [28]. 
Integration primarily occurs into transcriptionally active regions of the cellular genome [29, 
30], but can also be take place in resting cells [31, 32]. After entry into the cellular nucleus 
through the nuclear pore, HIV-1 DNA is then integrated into an active chromatin site close to 
the nuclear pore complex. [33]. The integrated viral DNA is referred to as a provirus or 
proviral DNA and persists until the cell dies [34, 35]. Because the provirus is integrated into 
the host genome, it is also passed on to daughter cells during normal cell division.  
2.2.2.4 Transcription and Translation 
The proviral DNA can enter a latent state where it is not transcribed or, more commonly, be 
transcribed into viral mRNA by the host RNA polymerase II. This transcription is initiated at 
the promotor in the 5´LTR region, where several binding sites for cellular transcription 
factors are found. The cellular RNA polymerase II transcribes a full-length copy of the viral 
RNA that can be spliced into several mRNA species or directly packaged into new virion 
particles as HIV-1 genomes. Initially the primary transcript is spliced into short mRNAs and 
translated into the regulatory proteins Tat and Rev. Tat binds to the transactivation response 
region (TAR) and promotes the elongation phase of HIV-1 transcription, thereby increasing 
the production of viral mRNA. Rev binds to the Rev response element (RRE), which 
facilitates the export of unspliced and incompletely spliced viral RNAs out of the nucleus for 
translation. Thereby Rev facilitates the switch from production of early regulatory proteins to 
production of late structural proteins. Nef increases the rate of CD4 endocytosis and 
lysosomal degradation as well as down-regulates the expression of major histocompatibility 
complex (MHC) class I molecules. These events facilitate both viral production and evasion 
of the host immune response. During the late transcription stages, the predominant mRNA 
species are unspliced or incompletely spliced. This involves the expression of the longer Gag, 
Gag-Pol and Env as well as Vif, Vpr and Vpu mRNAs. The mRNAs are translated in the 
cytoplasm near the endoplasmatic reticulum (ER). The Env protein (gp160) is synthesized in 
ER, and migrates through the Golgi complex where it undergoes glycosylation, which is 
essential for infectivity. Cellular proteases cleave gp160 into the surface proteins gp41 and 
gp120. Finally, the glycoproteins are transported to the plasma membrane [36, 37]. 
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2.2.2.5 Assembly, Release and Maturation 
Assembly of all the components is initiated near the plasma membrane of the host cell. When 
the HIV-1 particle buds from the cell it is immature and has poor ability to fuse with target 
cells. After release the PR cleaves the Gag and the Gag-Pol polyproteins into functional 
proteins forming the matrix, capsid and nucleocapsid as well as the viral enzymes. The 
maturation of the virion is final step of the HIV-1 replication cycle and the mature virions can 
infect other cells [38]. 
2.3 HIV-1 INFECTION 
2.3.1 Transmission 
HIV-1 is transmitted through sexual contacts, maternal-infant exposure, blood transfusions 
and contaminated injection equipment. Most transmissions occur through sexual contact, and 
heterosexual contact accounts for the majority of sexual transmissions [39]. The sexual 
transmission rates for HIV-1 from untreated infected persons ranges from 10% per exposure 
down to less than 0.1% [40, 41]. This wide range in transmission risk is influenced by many 
biological and behavioral factors. A major role determining the risk of transmission is the 
level of infectious virions that are present. During the early and late clinical stage of HIV-1 
infection the viral load is very high and therefore patients are more infectious during these 
stages. To establish a systemic infection only one or a few infectious virions need to succeed 
and in most cases HIV-1 infection is initiated with a single virion infecting a single target cell 
[40, 42]. A factor that can increase the risk of transmission is the presence of co-infections 
such as sexually transmitted diseases and genital ulcers [41, 43]. Behavioral factors are of 
importance for the actual transmission risk. For instance, when condoms are used correctly 
and when injecting drug users use sterile injection equipment the transmission risk is close to 
zero. Successful antiretroviral therapy (ART) has been shown to lower the level of viral load 
to undetectable levels and thereby the risk of HIV-1 transmission from individual patients as 
well as the spread of the infection at a population level is zero or extremely low (see section 
2.6). 
2.3.2 Pathogenesis 
In the absence of antiretroviral therapy, the course of HIV-1 infection goes through different 
stages, eventually ending in AIDS and death (Figure 3). After transmission there is an initial 
stage, referred to as the “eclipse phase”, during which the infection is established. During this 
phase, which lasts up to 10 days, the virus replicates and spreads from the site of entry to 
other tissues and organs. Next is the primary (or acute) infection phase, where HIV infection 
spreads to the lymphoid tissues and the systemic circulation of HIV virions takes place. At 
this stage viral replication increases rapidly and the viral load reaches very high levels (up to 
10
7
 copies of RNA per milliliter of blood). As a result of immune responses directed against 
this HIV-1 infection, flu-like symptoms may appear during this stage. Primary infection is 
also characterized by a transient decline in the number of primary target cells, i.e. the CD4
+
 T 
cells, which is caused by the viral cytopathic effect and the host immune response. Due to 
control by the immune response and possibly also the exhaustion of activated target cells, the 
primary phase ends with a decline in viral load to the so called viral set-point. At this point 
the levels of CD4
+
 T cells have been partially restored [44, 45]. The next phase is referred to 
as chronic infection or clinical latency. During this phase the viral load is stable or slowly 
increasing whereas the CD4
+
 T cell levels decline slowly in a roughly linear manner. At this 
point, patients typically are asymptomatic and unaware of their infection. Although this stage 
is clinically quiet, the infection is highly dynamic, with large numbers of CD4
+
 T cells being 
infected and killed each day. AIDS is the final stage of HIV-1 infection and takes place, on 
average, 8 years after infection. At this stage the virus has defeated the immune system, 
    
which is unable to control viral replication. This occurs gradually when the CD4
+
 T cells 
drops below 200 cells/µL. However, when the CD4 counts are 200-500 cells/µL early 
symptoms of immunodeficiency may appear. During the AIDS stage the CD4
+
 T cells 
continue to decline and the viral load rises. At the same time the infected individual may 
experience several different opportunistic infections, including pneumocystis pneumonia and 
fungal infections, as well as other diseases, including dementia and virus-induced tumors 
[45]. 
 
Figure 3. Typical course of HIV-1 infection.  
2.4 CELLS AND TISSUES INFECTED BY HIV-1 
2.4.1 Cell Types 
As previously described (2.2.2 Replication), HIV-1 initially attaches to the CD4 receptor, 
which is primarily expressed on CD4
+
 T cells, mainly on naïve, activated and memory T 
cells. To infect the target cell HIV-1 also requires the engagement of the co-receptor CCR5 
and/or CXCR4. Other co-receptors have been identified in vitro, but only CCR5 and CXCR4 
have been documented as co-receptors in vivo [46]. A viral classification based on co-
receptor usage has been established: R5 viruses (CCR5), X4 viruses (CXCR4) and R5X4 
viruses (CCR5 and CXCR4). The majority of infections are established by R5 viruses and 
during the course of infection X4 viruses can emerge, which happens in 50% of patients [47, 
48]. Activated and memory CD4 T cells primarily express CCR5 and are therefore thought to 
be the initial cells that are infected through mucosal transmission. Monocytes, macrophages 
and dendritic cells (DCs) also express CCR5, but to a lower degree [49-52]. Monocytes 
circulate in the peripheral blood and migrate to various tissues where they differentiate into 
macrophages. Conflicting results have been reported whether monocytes are infected. Several 
studies indicate that monocytes can be infected in vivo [53-55] whereas other studies show 
that this cell type is rarely found to be infected [56]. Several studies have shown evidence that 
different tissue-specific macrophages can become infected in vivo [57-60]. Discussions 
whether DCs are susceptible to HIV-1 infection or if they merely capture and transport the 
virions are ongoing [61, 62]. Hematopoietic stem cells (HPCs) express CD34 and are capable 
of long-term self-renewal and differentiation into either myeloid or lymphoid lineages. HPCs 
have also been proposed to be infected by HIV-1 in vivo [63]. Whether this cell type is 
infected or not is discussed in paper I. 
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2.4.1.1 CD4+ T Cells 
The memory CD4
+
 T cell populations have a significant role in the HIV-1 infection. During 
an individual’s lifetime the frequency of memory T cells undergo dynamic changes (Figure 
4). The different cell types express a distinct set of surface molecules, can be located in 
different tissues, and have various functions. At birth, all T cells in the peripheral blood are 
naïve and subsequently memory T cells are generated following antigen exposure [64]. 
During the primary immune response, antigen-specific naïve T cells (TNA) migrate to the T 
cell area of secondary lymphoid tissues to search for antigens presented by dendritic cells. 
When the TNA cells are exposed to an antigen they will undergo proliferative expansion and 
differentiation into cells with effector capacities. The activated effector T cells (TEFF) will 
migrate to infection sites to assist with the clearance of infection by orchestrating adaptive 
immune responses [65, 66]. While the majority of the TEFF cell population dies during 
clearance of infection the remaining cells will transition into various antigen-specific memory 
T cell subsets. These memory T cells have been divided into subsets characterized by their 
phenotypic and functional profiles, including central memory (TCM), transitional memory 
(TTM) and effector memory (TEM). The main subsets, TCM and TEM, have distinct homing 
capacities and effector functions [67, 68]. The TCM subset, which expresses the lymph node 
homing receptor CCR7, have the ability to home to secondary lymphoid organs and have an 
increased capacity to survive and proliferate after activation [68]. The TCM transitions into 
TEM after T cell receptor (TCR) triggering or, to a lesser extent, in response to homeostatic 
cytokines such as interleukin 7 (IL-7) and interleukin 15 (IL-15) [69]. The TEM subsets, 
which do not express CCR7, have direct effector functions after antigen stimulation. The TTM 
subset displays functional and transcriptional characteristics that are intermediate to the 
central and effector subset characteristics. TTM subsets express CCR7 as well as a marker 
important for the long-term maintenance of memory called CD27 [70]. During adulthood the 
levels of memory T cells are maintained through homeostasis. Thereafter, the memory T cells 
undergo the last phase referred to as immunosenescence. This phase starts around age 65 and 
is characterized by an altered proportion and functionality of memory T cells [64]. Recently, 
a new subset of memory T cells was observed in viral and tumor-reactive T cell populations, 
the T memory stem cell (TSCM). They have the ability to rapidly release cytokines on 
activation and a high proliferative capacity in response to IL-15. TSCM cells are the least 
differentiated memory T cell population and have the capacity to self-renew and generate all 
memory and effector T cell subsets [71]. In addition, studies on mouse models have 
established the existence of another new subset referred to as tissue-resident memory T (TRM) 
cell subset. This memory T cell subset is a non-circulating subset that resides in peripheral 
tissue sites. TRM cells have been shown to be important to antiviral host defense in epithelial 
tissues and these cells have  also been found in lung where they are designated to respond to 
pathogens previously encountered through lung mucosa [64, 72]. 
 
Figure 4. A schematic model for T cell differentiation.  
    
2.4.2 Tissue Compartments 
If HIV-1 is transmitted through sexual contact the virus will first replicate locally at the site 
of infection and thereafter migrate to lymph nodes where the replication intensifies due to a 
higher abundance of target cells. After the virus has established itself in lymph nodes it is 
broadly disseminated to the rest of the body where it establishes infection in cells located 
within various tissues. Most studies investigating HIV-1 infection have relied on analyses of 
peripheral blood, which is the most accessible compartment. However, several studies have 
shown that other tissue compartments harbor the majority of the virus as  the majority of 
lymphocytes are distributed in tissues such as lymph nodes, spleen and gut-associated 
lymphoid tissues (GALT) [73, 74]. The peripheral blood compartment harbors a low  
percentage of the total lymphocytes found in the body [75]. In contrast, the GALT 
compartment, which is the largest lymphoid organ in the body, harbors 60% of the 
lymphocytes, 40% of them being CD4
+
 T cells [74, 76, 77]. Due to the large amount of 
lymphocytes that are located in the GALT compartment it is not surprising that the GALT 
compartment plays an important role in HIV-1 infection. Studies have shown that this 
compartment is the primary site of viral replication and that during acute/early infection up to 
60% of the mucosal memory T cells are infected. Moreover, this compartment is thought to 
encounter the most substantial CD4
+
 T cell depletion during all stages of the disease [77]. As 
mentioned above, dendritic cells and other antigen presenting cells migrate to the lymph 
nodes where infection of CD4
+
 T cells occurs. Some studies suggest that the lymph node has 
a higher amount of HIV-1 RNA and DNA compared to peripheral blood [78, 79]. In addition 
to lymphoid tissue, virus can be detected in the central nervous system (CNS) throughout 
HIV infection [80-83].  
2.5 HIV-1 GENETIC VARIABILITY 
2.5.1 Sources of Genetic Variation 
HIV-1 has the capacity to rapidly develop a genetically diverse population from initially one 
or a limited number of infectious particles. This feature provides the virus with the ability to 
evade the host immune system, develop drug resistance during suboptimal antiretroviral 
therapy, and hinder the development of successful vaccines. Several unique mechanisms 
contribute to this effect: high viral turnover, a high mutation rate during viral replication, viral 
recombination and immune evasion. 
2.5.1.1 High Viral Turnover and Mutations 
During untreated HIV-1 infection the virus has high replication capacity and turnover rate, 
which contributes to the rapid evolution of HIV-1. The time from the release of a virion until 
it infects another cell and causes the release of a new viral particle is called the generation 
time. For HIV-1 the generation time is estimated to be approximately 2 days and the 
replication rate is thought to be as high as 10
10
 new viral particles per day in untreated 
infected persons [29, 84, 85]. 
During the HIV-1 replication cycle, point mutations are spontaneously generated throughout 
the viral genome by several mechanisms. The vast majority of genetic diversity is introduced 
by the HIV reverse transcriptase (RT) when it transcribes the viral RNA into dsDNA. Since 
the viral RT enzyme lacks proofreading mechanisms, these mutations will remain 
uncorrected. The overall mutation rate has been estimated to generate an average of 3.4×10
-5
 
mutations per base pair per replication cycle. Considering that the HIV-1 genome is 
approximately 10 kb this equals 0.3 mutations per genome and replication cycle [86, 87]. A 
second source of viral diversity takes place during the transcription of the viral genome which 
is mediated by the host cellular RNA polymerase II (RNAPII) complex. However, this 
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mechanism contributes to less than 3% of all mutations during replication and is therefore not 
a major contributor to the genetic diversity [88]. Another mechanism contributing to the 
genetic diversity of HIV-1 are the APOBEC3 host proteins: APOBEC3G and APOBEC3F. 
These host restriction factors function as innate inhibitors of retroviral replication by 
introducing G-A mutations. These APOBEC3G-induced G-A mutations are believed to occur 
during a single replication cycle and can result in stop codons within the HIV-1 genome and 
replication incompetent viruses – a process called hypermutation [89, 90]. However, the viral 
protein Vif counteracts the antiviral effects of APOBEC3G and F by targeting these proteins 
for degradation.  
2.5.1.2 Retroviral Recombination 
During reverse transcription the RT enzyme switches between the two ssRNA genome 
templates. By using information from both templates the process results in a hybrid viral 
DNA. This event is estimated to occur between 2 to 30 times per replication cycle. Although 
recombination occurs in all replication events, making all HIV-1 DNA molecules 
recombinants,  a single cell must be infected with two or more genetically distinct viruses to 
generate a recombinant that is genetically different from either of the two parental templates 
[91-93]. However, the majority of CD4
+
 T cells in peripheral blood contain only one copy of 
the HIV-1 DNA molecule implying a limited potential for virus recombination in these cells 
[56]. Despite being a rare event, recombination contributes significantly to HIV-1 diversity as 
evidenced by the existence of circulating recombinant forms.  
2.5.1.3 Immune Evasion 
After primary infection, the host immune system exerts considerable selection pressure on the 
infecting HIV-1 population. In fact, this immune pressure continues throughout the course of 
HIV-1 infection. Through Darwinian selective pressures the best-adapted, most “fit” genetic 
variants, are favored. Therefore, due to immune pressure, escape mutations arise which allow 
HIV-1 to evade the host immune system. These escape mutants have been shown to be 
transmitted from one host to another, thereby driving evolutionary changes also at a 
population level [94-96].  
2.5.2 Methods to Study HIV-1 Genetic Diversity 
Phylogenetic analysis is the study of evolutionary relationships through sequence 
comparison. By studying the relatedness between viral variants one can attempt to reconstruct 
the evolutionary history and explain the observed diversity. The sequencing data, retrieved 
through extraction of genetic material from viral RNA or DNA, can be used to construct 
phylogenetic trees and measure the genetic distance between viral sequences.  
2.5.2.1 Phylogenetic Analyses 
Phylogenetic analysis is a process whereby the use of mathematical algorithms, statistical 
methods and software programs are used to construct a phylogenetic tree that attempts to 
represent the evolutionary and/or genetic relationship between sequences. A phylogenetic 
tree, also called an evolutionary tree, is a branching diagram which shows the inferred genetic 
relationship between different sequences (see Figure 5 and Textbox 1 “Tree Terminology”). 
There are several approaches to construct a phylogenetic tree. The four major methods that 
can be used are distance, parismony, maximum likelihood (ML) and Bayesian. The 
constructed phylogenetic tree is unlikely to fully reproduce the “true” tree that represents the 
actual evolutionary relationship and each method has its advantages and weaknesses. Both 
the parsimony and the distance-based methods, such as neighbor-joining (NJ), are relatively 
fast and work well on closely related sequences. In contrast, ML and Bayesian methods are 
    
usually more accurate, but slower because they are computationally more complicated. For 
NJ, the optimal tree is generated by first creating a pair-wise distance matrix to estimate the 
evolutionary distances between the sequences. These matrices are then used to build a tree. 
While NJ does not explore several tree options, the parsimony method considers the optimal 
tree to be the tree requiring the fewest nucleotide or amino acid substitutions required over 
time to fit the sequences in the dataset. The maximum likelihood method explores how likely 
the sequences are to have evolved in a particular tree. An evolutionary model is used to assess 
the probability of a particular mutation. Thereby, the optimal tree has the highest likelihood 
of producing the observed data (see section below). Finally the Bayesian method uses a 
statistical model to search the phylogenetic tree by calculating the likelihood of a tree itself. 
 
 
 
Figure 5. Description of a phylogenetic tree. 
Evolutionary models are statistical descriptions of the process of nucleotide changes in the 
tree. To estimate the genetic distances between sequences in an alignment the models 
measure the nucleotide substitutions per site that have occurred and their most recent 
common ancestor. There are several models of nucleotide evolution. The simplest models, 
such as Jukes-Cantor assumes the following: 1) there are equal proportions of all nucleotides; 
2) that the ratio of transitions and transversions equals 1; and 3) that the probability of a base 
changing into any of the other three is equal. Since these assumptions do not reflect the true 
evolutionary path several more complex models have been developed. The general time-
reversible (GTR) model assumes that all substitutions have their own rate, a symmetric 
substitution matrix (A → T = T → A) and variable base frequencies. In addition, there are 
models to describe the rates of variation among sites in a sequence such as the gamma 
distribution model which assumes that substitution rates vary between sites in a gamma-
distributed manner. Sometimes the models also allow a proportion of sites in the sequence are 
invariable. Reliability tests are used to evaluate the constructed trees robustness or accuracy. 
There are a number of measures for this with the most common being a resampling method 
called bootstrapping. By creating pseudo-replicate datasets through resampling with 
replacement, bootstrapping allows you to assess the trees reliability.  Each node is given a 
number which represents the reliability of the placement of individual branches in the optimal 
tree given the sequence data and the assumptions used to construct the tree. 
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 Tree topology is the branching pattern. 
 The branches define the relationship between the sequences.  
 The branch length represents the number of genetic changes that have occurred between each sequence  
referred to as the genetic distance. The longer the branch, the greater the genetic distance is between two 
sequences. 
 The taxa are the tips of the tree and in our case represent the actual viral sequence. Can be specified 
with a specific symbol to represent a different cell type and tissue. 
 A clade is a grouping of an ancestor and all of its descendents. 
 The node is the point where the branches are connected and represent the assumed ancestral sequence 
from which the tips or taxa descend. 
 A distance scale is used to show the amount of genetic change in the number of nucleotide substitutions 
per site, i.e. the number of changes or substitutions divided by the length of the sequence. 
 A rooted tree suggests that the path from the root to a node represents an evolutionary path, with the 
root being the common ancestor of all taxa. 
 An unrooted tree shows the genetic relationship between taxa or sequences.  . 
 An out-group can be included in unrooted tree, which is a one or more sequences that falls outside the 
group of sequences being studied. All sequences of interest are more closely related to each other than 
they are to the out-group. 
 
 
Textbox 1. Tree terminology 
 
2.5.2.2 Average Pairwise Distance 
Average pairwise distance (APD) (used in paper I) is a method used to estimate the genetic 
diversity between sequences by calculating the proportion of nucleotide differences between 
each pair of sequences. The method can be used to compare the genetic diversity of HIV 
within different cell types, compartments or at different time points. For example, the viral 
populations in acute/early HIV-infected patients typically have low genetic diversity and 
APD, consistent with the infection by a single or small number of viral variants [97]. In 
contrast, the viral populations within an HIV-infected patient who has been untreated for 
several years will have a high genetic diversity and APD. However, one should keep in mind 
that pairwise methods simply evaluate the number of differences and, therefore, this can be 
an underestimate of the true evolutionary distance. Also, if a patient is infected with two or 
more diverse HIV-1 variants, the genetic diversity and ADP will be high during acute 
infection. 
2.5.2.3 Compartmentalization 
A viral subpopulation can become compartmentalized if trafficking and gene flow is 
significantly restricted between the different subpopulations. Due to the high mutation rate of 
HIV-1, the genetic distance between subpopulations can increase rapidly. Factors such as 
different selective pressures by the immune system and suboptimal drug distribution can 
increase the compartmentalization of viral populations. The analyses used to detect 
compartmentalization of viral populations between different compartments can also be used 
to detect compartmentalization between different time points. There are two different types of 
compartmentalization analyses (used in papers III and IV) 1) tree-based, which use a 
phylogenetic tree to detect compartmentalization and 2) distance-based, which are based on 
pair-wise distance. These compartmentalization analyses are only as reliable as the topology 
of the phylogenetic tree (tree-based) or as reliable as the pairwise distance values (distance-
based).   
    
2.5.2.4 Evolutionary Rate Estimations 
Another way to study genetic diversity and genetic evolution is to measure the rate of 
mutation accumulation. Due to features such as high error rate and high turnover, HIV-1 viral 
populations accumulate many mutations over time. By comparing molecular sequence data 
from two time points the evolutionary rate can be estimated. This estimation can be done 
using different statistical methods such as linear regression, maximum likelihood and 
Bayesian inference. A challenge with these estimations is that single nucleotide sites may 
experience sequential mutations. These processes are difficult to discern, especially over a 
longer evolutionary time.   
2.6 ANTIRETROVIRAL THERAPY 
2.6.1 History and Current HIV-1 Disease Management 
Almost all untreated HIV-1 infected patients will develop AIDS. With a mortality rate well 
over 95%, this makes HIV-1 one of the most lethal diseases known to mankind. Although no 
cure or effective HIV vaccine exists, the remarkable development of HIV-1 treatment has 
dramatically increased the life expectancy of millions of HIV-1 infected individuals. By 
1987, a total of 71,751 AIDS cases had been reported to the World Health Organization 
(WHO) and 5 to 10 million people were estimated to be infected with HIV worldwide [98]. 
During 1987 the first antiretroviral drug, azidothymidine (AZT), became available. However, 
it took several years until the death rates from AIDS dramatically fell for the first time. The 
explanation for this decrease was the development of new drugs and the introduction of a 
more powerful combination therapy regimen using a “cocktail” of drugs. This new treatment 
strategy, often referred to as highly active antiretroviral therapy (HAART) or combination 
antiretroviral therapy (cART), was introduced in 1996. Today there are six distinct classes of 
antiretroviral drugs. By giving a combination of drugs simultaneously from two or more 
different classes, long-term viral suppression can be achieved, as treatment with cART stops 
or significantly reduces viral replication and prevents the evolution of drug resistance [99-
102]. If treatment is successful viral replication is suppressed and the plasma viral load is 
reduced to less than 50 RNA copies/mL. However, despite several years of successful 
therapy one can still detect low-levels of viremia [103]. Virological treatment failure and 
development of drug resistance occurs when the viral load rebounds or if the level is not 
decreased sufficiently despite cART. Factors causing virological failure include lack of 
adherence, poor drug tolerability and drug-drug interactions [84]. 
As of March 2015, 15 million people living with HIV were accessing antiretroviral therapy, 
which is an increase from 13.6 million in June 2014 [23]. In 2013 a worldwide treatment 
target, called 90-90-90 was developed to help end the AIDS epidemic. This strategy, 
proposed by UNAIDS, has the ambitious target that by 2020 90% of all individuals living 
with HIV will be aware of their HIV status, 90% of all individuals diagnosed with HIV will 
receive antiretroviral treatment (ART) and 90% of all individuals receiving ART will have 
viral suppression [104]. The recent 2014 progress report from European centre for disease 
prevention and control (ECDC) showed that Sweden is the only country in Europe and 
central Asia which is currently reaching all three targets [105]. 
2.6.2 Available and Potential Antiretroviral Drugs 
Although there are many potential targets in the HIV-1 replication cycle that could be 
possible for therapeutic interventions, only a few targets have led to successful drugs. Today 
there are about 25 antiretroviral drugs that have been approved for treatment of HIV-1 
infection. Out of the six different classes of antiviral drugs the majority of antiretroviral 
compounds belong to three classes: nucleoside reverse transcriptase inhibitors (NRTIs); non-
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nucleoside reverse transcriptase inhibitors (NNRTIs); and protease inhibitors (PIs). The 
reverse transcriptase inhibitors, NRTIs and NNRTIs, target the HIV-specific RT enzyme and 
affect the DNA polymerization activity of the enzyme and block the generation of full-length 
viral DNA. NRTIs, such as abacavir (ABC), lamivudine (3TC), and tenofovir (TDF), are 
dNTPs lacking the 3-hydroxyl group that is necessary for DNA elongation. The NRTIs 
function as substrates for the RT during reverse transcription and thereby terminate the DNA 
strand of HIV-1 during transcription [102, 106], hence they are sometimes called chain 
terminators. The other subclass of RT inhibitors is the NNRTI subclass, which by non-
competitive binding to the RT enzyme inhibit the enzyme activity. Efavirenz (EFV) is an 
example of a NNRTI which is often chosen as part of first-line cART today [102, 107]. The 
PIs interfere with the essential viral enzyme protease and inhibit the maturation of viral 
particles. PIs block the gag-pol polyprotein cleavage, thereby leaving them non-infectious. 
Atazanavir (ATV) and darunavir (DRV) are examples of two PIs currently being 
recommended as first line therapy options [102, 108]. Another drug class is aimed at blocking 
viral entry. This step can be targeted by attachment inhibitors, chemokine receptor 
antagonists and fusion inhibitors. To date there are two approved drugs:  maraviroc (MVC) 
and enfuvirtide (T-20). MVC is a small molecule CCR5 chemokine receptor antagonist, 
which prevents the binding of gp120 to the co-receptor and hence prevents viral entry. T-20 
is a peptide, which binds to the HIV-1 gp41 protein and thereby prevents the fusion of the 
virus to the host cell [109, 110]. Integration is another step in the viral replication cycle which 
can be targeted by drugs. Raltegravir (RAL) inhibits strand transfer and blocks integration of 
the viral genome into the cellular DNA, by binding to a specific complex between the viral 
integrase and the viral genome [102, 111]. 
There are several potential steps in the viral replication cycle which are under intense 
investigation for future drug discovery. For example, during transcription, the HIV-1 
regulatory protein Tat binds to the viral RNA element TAR. Since this mechanism is unique 
to HIV-1 it is a highly desirable step to target in the HIV-1 replication cycle. Although 
several small-molecule inhibitors targeting HIV-1 transcription have been identified, none 
have passed phase I clinical trials. Another potential target is virus assembly and viral release. 
Progress have been made in this area but unfortunately insufficient antiviral activity have 
terminated these compounds in early phase trials [102]. 
2.7 THE HIV-1 RESERVOIRS 
Although HIV-1 viremia can be suppressed and maintained at low levels for prolonged 
periods of time, cART alone cannot eradicate HIV-1 in infected individuals. Latency is a 
common feature of retroviruses and in the case of HIV-1 enables the virus to survive and 
persist despite host immune response and antiviral therapy. During the latent state, the 
integrated HIV-1 virus is transcriptionally silent and persists solely as information. However, 
if the latently infected cell is activated, e.g. during suboptimal treatment or treatment 
interruption, the latent state is reversed and leads to rapid viral rebound. The latent HIV-1 
reservoir is defined as a cell type or anatomical site where a replication-competent form of 
the virus can accumulate and persist stably during optimal cART. When HIV-1-infected 
individuals stop treatment they exhibit plasma viral rebound which arises from replication-
competent virus that persists within these latent reservoirs. Therefore, defective proviral 
sequences do not represent the true latent reservoir as cells containing defective proviral 
sequences cannot produce HIV-1 upon reactivation [112]. These long-lasting latent reservoirs 
are the main impediment to a cure for HIV-1, and therefore, there is great interest in 
identifying which cell types and anatomical sites act as reservoirs during cART (see section 
2.7.2).  
    
2.7.1 Dynamics during Antiretroviral Therapy 
In 1995, studies showed that suppressive therapy caused plasma viral loads to decrease 
exponentially [85, 113]. Hopes for HIV-1 eradication arose when cART was introduced and 
showed a reduction of plasma viral load to below limit of detection [114-116]. But 
unfortunately, it was soon evident that the decay rate of the pool of latently infected cells was 
extremely slow in patients treated with antiretroviral therapy. Statistical analysis suggest that 
these cells, with a half-life of approximately 44 months, would require over 60 years of 
suppressive cART to be eradicated [117-119]. The viral decay after initiation of cART can be 
divided into four phases. The different phases represent the death or elimination of different 
infected cell types. The first phase after initiation of cART is characterized by its rapid drop 
in plasma viral load, reflecting the short half-life (1-2 days) of the activated virus-producing 
CD4
+
 T cells [85, 113]. The second phase of decay is slower and represents the release of 
virus from other cell populations with a half-life of about two weeks. The cells thought to be 
responsible for this decay are partially activated CD4
+
 T cells and macrophages [116, 120-
122]. However, this is uncertain and other cells have also been proposed to be linked to the 
second phase of decay. During phase three the viral decay is much slower with a half-life of 
39 weeks and subsequently during phase four the HIV-1 RNA levels are stable at very low 
levels with no perceptible viral decay. Despite years of successful cART, sensitive assays 
with limits of detection down to less than 1 copy of HIV-1 RNA/ml revealed traces of 
viremia in many patients with a median viral RNA level of 3 copies/ml [103, 123, 124]. This 
residual viremia has a very short half-life and therefore it is continuously replenished by 
some mechanism [29]. However, the origin of this residual viremia during cART is a matter 
of controversy and several hypotheses have been suggested (Figure 6). The first hypothesis 
suggests that ongoing HIV-1 replication occurs in sanctuary sites where drug penetration is 
low or absent. A second explanation is that cART inhibits all or almost all viral replication 
and that the residual viremia is released from long-lived T cells that are reactivated. Another 
hypothesis suggests that low-level of HIV-1 RNA is released from other undiscovered 
reservoirs (discussed in 2.7.2). However, recent studies suggest that the reservoir is not only 
driven by T cell survival but is also maintained by homeostatic proliferation of latently 
infected CD4
+
 T cells. These cells may be the source of the low-level of HIV-1 RNA found 
in patients on cART [125] (paper IV). 
 
Figure 6. Mechanisms of HIV-1 persistence. 
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2.7.1.1 Viral Replication during Suppressive Therapy 
There are several approaches that can be used to investigate whether ongoing replication 
occurs during suppressive therapy. One approach is to study genetic change during 
suppressive therapy. The detection of viral evolution during therapy would be a clear 
indication that cART does not completely stop viral replication. However, analyses of this 
type can be complicated if patients are not fully adherent to cART. Therefore, the detection of 
HIV-1 evolution in a small subset of patients could rather be evidence of poor adherence than 
evidence of ongoing replication. Several studies fail to detect strong evidence for evolution in 
the majority of patients on cART [46, 126, 127] (papers III and IV), but there are also 
studies that support the hypothesis that replication occurs during suppressive therapy [128]. 
One report, with results implying ongoing viral replication in the GALT, showed a decrease 
in the amount of un-spliced HIV-1 RNA in CD4
+
 T cells isolated from the terminal ileum 
during raltegravir intensification [129]. Another study by Fletcher and colleagues, revealed 
that replication continues in the lymph nodes of some individuals receiving successful 
treatment. According to this study, the ongoing replication is explained by the lower 
concentrations of antiviral drugs in these tissues compared to peripheral blood [130].  
Another approach to study whether replication occurs during cART is to use certain virologic 
measures to detect unintegrated forms of the viral genome. Detection of linear unintegrated 
HIV-1 DNA would indicate recent infection since this form of DNA is targeted by 
exonucleases and is labile until integrated into cellular DNA [131, 132]. When integration is 
blocked circular forms of the HIV-1 genome, especially 2-LTR circles, can arise [133, 134]. 
The circular forms are dead ends with respect to replication but could also indicate recent 
infection. However, the stability of these HIV-1 DNA forms is still under discussion and 
therefore the significance of finding these forms of HIV-1 DNA during treatment remains 
unclear [135, 136]. 
Another way to test the hypothesis that viral replication continues during suppressive therapy 
would be to demonstrate that intensification of standard cART would further reduce the level 
of viremia. Several studies, using different drugs, have shown that intensification of cART 
does not affect the level of persistent viremia [129, 137-139]. A study by Buzón and 
colleagues did however show increased levels of episomal viral cDNA during raltegravir 
intensification. This study indicates that ongoing replication may occur during cART and that 
replication is completely or partially blocked during intensification [140]. The CNS has been 
proposed to be a possible sanctuary site where HIV-1 can continue to replicate despite cART. 
Since the CNS is separated from the circulating blood by the blood-brain barrier, some 
antiviral drugs penetrate the CNS poorly. Antiviral therapy is known to reduce the HIV-1 
RNA levels in the cerebral spinal fluid (CSF) in most patients [82, 141, 142]. However, 
recent intensification studies could not detect a reduction in CSF viral loads indicating that 
there is little or no ongoing replication in this compartment [143]. 
2.7.2 Source of Persistent HIV-1 during Antiretroviral Therapy   
The establishment of latently infected cells is a rare event. However, although the pool of 
latently infected cells is very small it is extremely important since without life-long cART 
viral rebound occurs within weeks of treatment interruption [144]. One well-defined reservoir 
is a small pool of latently infected resting memory CD4
+
 T cells [145, 146]. When resting 
memory CD4
+
 T cells are activated in response to an antigen they undergo a burst of cellular 
proliferation and differentiation, giving rise to effector cells. Although most effector cells die 
quickly a subset reverts to a memory state. A plausible hypothesis is therefore that HIV-1 
latency is established when activated CD4
+
 T cells, which are highly susceptible to HIV-1 
infection, become infected by HIV-1 and survive long enough to revert back to a resting state 
[85, 113, 147].  Out of the memory CD4
+
 T cell subsets, TCM and TTM have been shown to 
    
contribute most to the HIV-1 reservoir during therapy [125] (discussed in paper III). In a 
recent study it has been shown that the stem cell-like memory T cell subset, TSCM, despite 
their low frequencies, may be of importance for HIV-1 persistence due to their ability to self-
renew, resist apoptosis and survive for long periods of time [148]. Another T cell subset that 
has been demonstrated to contain HIV-1 DNA in patients on long-term suppressive therapy is 
TNA cells. Compared to memory T cell subsets this population contains a lower frequency of 
HIV-1 DNA [149] (papers III and IV).  
Some phylogenetic analyses indicate that the majority of the low-level HIV-1 RNA isolated 
and sequenced from the plasma during therapy is genetically identical. Interestingly, these 
plasma-derived HIV-1 RNA sequences are not often found in intracellular HIV-1 DNA 
isolated and sequenced from circulating resting CD4
+
 T cells [150]. Hypotheses for the origin 
of these clonal plasma-derived sequences are: 1) they represent virus being continuously 
released from a long-lived cell which was infected before initiation of cART; 2) they 
represent virus released when a large subset of cells, which were infected by the same variant 
before initiation of cART, are reactivated and release virions; or 3) they represent progeny 
virus being released from an infected progenitor cell as it divides. Progenitor cells that have 
been suggested to be infected are the HPCs [63]. However, whether this cell population is 
infected or not is unclear [151] (paper II). Other cell types that have been proposed to play 
an important role in maintaining the HIV-1 reservoir in patients on cART are monocytes and 
macrophages. In some studies these cells have been shown to contain HIV-1 DNA [152-154]. 
However, to date, it is unclear what role these cells play in maintaining the HIV-1 reservoir in 
patients on long-term treatment (discussed in papers III and IV).   
Beside peripheral blood and bone marrow, a number of anatomical sites have been proposed 
to act as reservoirs including the gastrointestinal (GI) tract, lymph nodes, central nervous 
system (CNS), genital tract, semen and the lung. If these anatomical compartments have 
suboptimal drug penetration or are non-permissive to immune surveillance viral replication 
may take place at these sites. Studies have shown that the majority of the lymphocytes are 
sequestered in the GI tract and thereby it is not surprisingly GALT has been proposed as a 
major HIV-1 reservoir in patients on long-term cART [155-159]. Lymph node tissue, which 
also contains numerous memory CD4
+
 T cells, may be another important anatomical 
compartment that may serve as an important reservoir. In untreated patients, HIV-1 infection 
is detected in microglia and perivascular cells [160]. If these cells or other cells in the CNS 
act as a latent reservoir during cART, they also need to be targeted in order to cure HIV-1. 
2.7.3 Methods to Study HIV-1 Reservoirs 
HIV-1 persistence is the major obstacle to eradication and finding strategies to reduce or 
totally eradicate HIV-1 reservoirs is a major challenge. Therefore, it is crucial to find methods 
that accurately measure the HIV-1 reservoirs. There are several factors that must be taken 
into account when measuring persistent HIV-1 infection. Most of the work investigating the 
reservoir has relied on studies of peripheral blood. However, findings suggest that the 
reservoir is largely established and maintained in tissues, and that the infected cells 
circulating in blood may not necessarily be representative of the much larger population of 
infected cells in tissue. Therefore, it is important to decide in which body compartment and 
cell type that one should measure the HIV-1 reservoir. Another critical issue is the status of 
the virus. If the virus is replication-competent it has the ability to replenish the reservoir if 
cART is interrupted. However, if the virus is replication-incompetent it is dead-end virus and 
may not need to be targeted during eradication attempts. A final aspect to take into account is 
whether the infected cell is quiescent or activated.  
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Currently, there are several methods used to study the reservoir. The different methods often 
address different questions such as the size of the reservoir, the composition of these 
reservoirs, or the capacity of latent reservoirs to produce virus.  All these assays provide new 
insights and are valuable for studying the reservoir. However, each method has its advantages 
and disadvantages (Table 1). Therefore, it is crucial to recognize what the assay is measuring 
and what the goal is for a particular clinical study.  
 
Table 1. Advantages and disadvantages. 
Measurement (Assay) Advantages Disadvantages 
Plasma-Derived HIV-1 RNA  
(SCA) * 
[123] 
-Measures ongoing viral 
production  
-Relatively inexpensive 
-Does not directly detect the 
frequency of latently infected 
cells  
-Patients on long-term cART 
close to limit of assay detection 
Replication competent virus 
(QVOA) * 
[117, 147, 161] 
-Direct measurement of 
replication competent virus, or 
number of proviruses capable of 
productive infection 
-Requires large quantities of 
cells 
-Expensive 
-Time consuming (2-3 weeks) 
-Limited dynamic range 
-Does not detect all functional 
proviruses  
Total HIV-1 DNA  
(qPCR or ddPCR) * 
[162, 163] 
-Inexpensive 
-Easy and quick  
-For ddPCR absolute 
quantification 
-Also detects defective 
proviruses which may not pose 
a barrier to a cure 
Integrated HIV-1 DNA  
(Alu-PCR) * 
[164] 
-Excludes unintegrated HIV-1 
DNA 
-More accurate than QVOA 
-Detects defective proviruses  
-Does not detect proviruses too 
far from Alu sequence (a 
correction factor can be used to 
account for this issue) 
2-LTR circles 
(qPCR or ddPCR) * 
[165, 166] 
-Used to measure ongoing 
replication based on the 
assumption that these circles are 
labile 
-For ddPCR absolute 
quantification 
-Does not detect integrated 
proviruses 
Cell-associated HIV-1 RNA 
[167-169] 
- Direct measures of cell 
associated HIV-1 RNA, 
unspliced RNA or multispliced 
RNA  
- Inexpensive, easy, and  quick  
- Measures intracellular HIV 
transcription 
 
-Detects abortive and defective 
transcripts which may not result 
in viral proteins 
 
 
*Method described in method section. 
 
    
2.7.3.1 Novel Assays to Study the HIV-1 Latent Reservoir 
There is an intense interest in developing new highly sensitive methods that can be useful in 
curative interventions and/or to identify HIV-1 infected individuals with such a low reservoir 
size that they may be able to interrupt antiviral therapy. One such novel approach utilizes the 
host immune response against HIV-1 antigens to quantify the latent reservoir. This method, 
called luciferace immunoprecipitation systems (LIPS), detects HIV-1 specific antibodies 
against antigens such as gp120, gp41, RT and p24. In a recently published paper, Burbelo and 
colleagues showed that a loss of antibodies against p24 and lower responses to gp41was 
associated with an HIV-1 curative state [170]. The so called murine viral outgrowth assay 
(MVOA) is a new method used to evaluate curative strategies. In this assay PBMCs or 
purified CD4
+
 T cells from HIV-1 infected participants with undetectable plasma viral loads 
are transferred into immunocompromised mice to see whether this results in viral 
amplification. This method could also be used to detect viral reservoirs within the peripheral 
blood of SIV infected macaques used in eradication studies. In the published study, 
replication-competent HIV-1 was successfully detected in all studied HIV-1 infected 
participants as well as from all elite controllers (HIV-1-infected individuals who naturally 
maintain undetectable viral loads and high CD4 counts without receiving cART). 
Interestingly, replication-competent virus was amplified from one elite controller using the 
MVOA but not when using the standard QVOA, indicating that the MVOA may be more 
sensitive than the QVOA [171]. However, a disadvantage with the MVOA assay is that it is 
expensive compared to PCR-based assays. Another promising novel approach to quantify 
latently infected cells is the so called tat/rev induced limiting dilution assay (TILDA). This 
assay measures the frequency of cells with inducible tat/rev multiply spliced HIV-1 RNA, 
which are usually absent in latently infected cells but induced when viral reactivation occurs. 
The assay combines sensitive detection of tat/rev multiply spliced HIV-1 RNA and maximal 
activation of CD4
+
 T cells in a limiting dilution format. Results from a recent study of this 
assay showed that the frequency of latently infected cells estimated using TILDA was almost 
50 times higher than the frequency measured using QVOA, and 6-27 times lower than the 
frequency measured using PCR-based assays. Although this assay may be an overestimate of 
the true latent reservoir it is a promising assay due to its attractive characteristics such as it is 
sensitive, quick, covers a wide dynamic range and only requires 10 ml of blood [172]. 
2.7.4 Eradication Strategies 
Due to the success of cART, the life expectancy of an individual living with HIV-1 in a high 
income country is close to life expectancy of uninfected people. However, life-long therapy 
and stigmatization remain. Furthermore, the access to care for all HIV-1 individuals is a 
tough challenge. Another issue with the need for life-long cART is that little is known about 
the long-term toxicity (>20 years) of antivirals. Finally, the lifetime treatment costs associated 
with cART represents another argument for developing a cure for HIV-1 infection. 
Eradication of HIV-1 is one of the major challenges of our time. In developing new curative 
strategies there are two forms of a cure which may be achieved: a sterilizing cure or a 
functional cure. A sterilizing cure is the ideal model in which all traces of the virus would be 
eradicated from the body. With functional cure, also referred to as viral remission, the aim is 
to give individuals living with HIV-1 the possibility to stop treatment, at least for a defined 
period, and still be without risk for transmission and/or significant plasma viral rebound. In 
this case HIV-1 DNA can still be detected, indicating that replication-competent virus may be 
present as a latent reservoir.  
The interest for an HIV-1 cure intensified after an infected man named Timothy R. Brown, 
also known as the ‘Berlin patient’, exhibited evidence of an HIV-1 cure after receiving an 
allogeneic hematopoietic stem cell transplant. Brown was diagnosed with HIV-1 in 1995. 
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After many years of successful therapy he was diagnosed with acute myeloid leukemia 
(AML) and in 2007 he underwent an allogeneic hematopoietic stem cell transplantation from 
a donor homozygous for a deletion in the gene that encodes for CCR5 [173]. Brown stopped 
cART approximately seven years ago and has had no detectable virus in his plasma by 
standard assays [174], i.e. appears to be cured. Although, Timothy Brown is a proof of 
concept for a curative strategy other studies have given some hopeful results. Recently 
Henrich and colleagues conducted a study where two HIV-1 positive lymphoma patients in 
Boston received allogeneic hematopoietic stem cell transplants using cells from wild-type 
CCR5 donor [175]. Unfortunately, both individuals demonstrated viral rebound 3 and 8 
months after cession of cART [176], indicating that these transplants delayed viral rebound 
but did not result in a cure. Other studies have used approaches to genetically modify CD4
+
 T 
cells [177, 178] or stem cells [179] in order to make the cells resistant to HIV-1. However, 
stem cell transplants and gene modifying strategies are expensive and possibly not scalable to 
resource limited areas. 
Since HIV-1 typically has the ability to rebound soon after cART interruption sustained viral 
remission is a challenging goal. Studies have shown that very early initiation of cART 
reduces the frequency of cells containing HIV-1 DNA integrants [180, 181]. Unfortunately, 
recently it became evident that virus can remain hidden for years before eventually 
rebounding. This was shown in a study of a baby from Mississippi, who initiated therapy 
within 30 hours after birth [182]. The infant stopped cART after 18 months because the baby 
was lost to follow-up care and seemed to be cured but eventually after 27 months off cART 
viral rebound occurred [183]. Recently, a study by Saez-Cirion and colleagues presented 
promising results which showed that early treatment (<10 weeks after primary infection), for 
a median of 3 years resulted in virological control following cART cessation for an average 
time of nine years. Replication-competent virus has been isolated from these patients but viral 
production appears to be controlled by the immune system [184]. However, relying on early 
cART to achieve a possible functional cure means that diagnosis and treatment must occur 
very soon after infection, which rarely is the case.  
A current focus of HIV-1 cure-research is called “shock and kill”. This strategy is based on 
the hypothesis that cART prevents infection of new cells and aims to eliminate all latently 
infected cells capable of producing infectious virions by treating patients on cART with 
latency reversing agents. In short, by reactivating all latently infected cells in patients on 
cART it is presumed that these cells will die from viral cytopathic effects or be killed by the 
immune response directed against them. In theory, this strategy will eliminate the latent 
reservoir. Histone deacetylase is involved in maintaining HIV-1 latency and therefore histone 
deacetylase inhibitors (HDACi) are candidates as latency reversing agents. The findings that 
the HDACi, vorinostat, can reactivate HIV-1 transcription in patients on suppressive therapy 
showed that latency is not completely irreversible [185]. Other studies using the same 
molecule or a molecule from the same family have also shown that latency reversing agents 
induce HIV-1 transcription in latently infected cells. But unfortunately, these studies do not 
seem to significantly reduce the size of the reservoir [186, 187]. A recent in vitro study 
revealed that virus reactivation did not cause the elimination of latently infected cells by viral 
cytopathic effect or cytolytic T lymphocyte response. This finding indicates that for latency 
reversing agents to be effective, sufficient immune response is needed. Therefore, one 
approach to eliminate HIV-1 infection would be to induce transcription from quiescent HIV-1 
proviruses followed by targeted immunotherapy to clear infected cells [188].  
Ongoing potential strategies to eliminate latently infected cells utilize cytomegalovirus as a 
novel persistent vector to deliver HIV-1 antigens [189] and highly broadly neutralizing 
antibodies [190]. Moreover, immune modulatory therapies used in cancer treatment may be 
able to activate antigen specific T cells. Ongoing research show that so-called immune 
    
checkpoints, such as programmed death 1 (PD-1) and cytotoxic T lymphocyte antigen 4 
(CTLA-4), expressing cells are enriched for HIV-1 DNA and may be used as biomarkers to 
identify the viral reservoir. Furthermore, these ligands inhibit viral reactivation and thereby 
have a role in maintaining the HIV-1 reservoir. By blocking these molecules with immune 
checkpoint blockers, HIV-1-specific immunity is presumed to be restored and viral 
replication reactivated [191-193]. This was shown in a study where PD-1 blockade enhanced 
SIV-specific immunity in Rhesus macaques [194]. To date, no single drug or intervention has 
resulted in anything near an effective sterilizing or functional cure. Therefore, effective 
eradication of HIV-1 from a chronically infected person will most likely require several non-
overlapping interventions, including: (1) long-term suppressive therapy, (2) agents aimed at 
directly reversing transcriptional latency (e.g., with drugs such as the HDAC inhibitors and 
other chromatin modifiers), and (3) immunotherapy including agents that reverse the 
inflammatory and immunoregulatory signals that promote latency and viral persistence. An 
example of a potential alternative to eliminating infected cells or latent viral reservoirs is to 
use RNA-based anti-HIV-1 gene therapeutics to achieve long-term silencing of the HIV-1 
genome.  
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3 MATERIALS AND METHODS 
3.1 STUDY DESIGN AND PATIENT MATERIAL 
All participants in the studies presented in this thesis are part of two well- established cohorts 
at University of California, San Francisco. The OPTIONS Cohort, is an ongoing longitudinal 
observational cohort of individuals enrolled within six months of HIV-1 antibody 
seroconversion and followed approximately every third month throughout the course of HIV 
disease. The evaluation of the participants with a possible acute/early infection includes 
detailed HIV-1 testing, exposure history and several laboratory analyses such as CD4
+
 T cell 
count. The second cohort is the SCOPE cohort, also an ongoing longitudinal study of about 
1,500 HIV-1 infected and uninfected individuals. All participants are seen and interviewed at 
four-month intervals to perform plasma HIV-1 RNA level measurements and routine T cell 
immunophenotyping as well as to ascertain four criteria: (1) current medication, (2) 
adherence to medication, (3) recent intercurrent illnesses, and (4) recent diagnoses or 
hospitalizations. For each participant cohort, the date of HIV infection was estimated as the 
midpoint between the last HIV-1 negative test and the first HIV-1 positive test.  
In paper I peripheral blood samples from 30 participants were analyzed. For 19 participants 
GALT samples were analyzed. For this study we included 10 participants who initiated 
therapy during acute/early infection (initiated therapy within 3 months after infection) and 20 
participants who initiated therapy during chronic infection. All participants maintained HIV-1 
RNA levels below 40 copies/mL in the year preceding the blood draw. At all sample 
collections, the CD4
+
 T cell counts ranged from 400 to 1200 cells/μL. For detailed patient 
characteristics and therapeutic regimens please see paper I. 
The samples analyzed in papers II-IV were from the same 8 HIV-1 subtype-B-infected 
individuals. For these studies we included five participants who initiated therapy 1–3 months 
after estimated time of infection (acute/early infection group; participants 1–5) and three who 
initiated therapy >1 year after estimated time of infection (chronic infection group; 
participants 6–8). All participants had undetectable viremia (ie, <40–75 HIV-1 RNA 
copies/mL) for at least three years after the initiation of therapy. At the on-therapy sample 
collection time points, their CD4
+
 T cell counts ranged from 500 to 1500 cells/μL. For 
detailed patient characteristics and therapeutic regimen please see papers II-IV.  
 In paper II  paired bone marrow and peripheral blood samples were analyzed. 
 In paper III paired GALT and peripheral blood samples were analyzed. These 
samples were isolated at the same time point as the samples analyzed in paper II. In 
addition, plasma samples before initiation of therapy were analyzed. The plasma 
samples were collected 0-180 days before initiation of therapy except for one 
participant whose plasma sample was collected 14 days after initiation of therapy.  
 In paper IV additional paired GALT and peripheral blood samples were analyzed. 
These samples were collected 7-9 months after the samples described in papers II 
and III. In addition we analyzed lymph node tissue speciemens from two of the 
participants.  
3.2 ETHICAL CONSIDERATIONS 
All participants in the studies presented in this thesis provided written informed consent prior 
to participation in the study. The studies were approved by the institutional review boards at 
the Karolinska Institutet, Stockholm (papers I-IV), the University of California, San 
Francisco (papers I-IV), the John Hopkins University School of Medicine, Baltimore (paper 
I) and the Western Sydney Health Department for the Westmead Millennium Institute for 
Medical Research, Sydney (paper IV). 
    
3.3 METHODS 
To quantify and genetically characterize HIV-1 DNA from cells and HIV-1 RNA from 
plasma we used different methods described briefly below. For more details please see the 
material and methods section for each paper. 
3.3.1 Fluorescence Activated Cell Sorting 
To characterize HIV-1 genetic populations in papers II-IV, a broad spectrum of cells were 
isolated using fluorescent activating cell sorting (FACS). FACS is a method which enables a 
mixture of different cells to be divided into specific cell types according to the specific 
phenotype of the cells. Different cell types have different antigenic and other markers on their 
surface that can be tagged using fluorescent probes, which are typically monoclonal 
antibodies that have been conjugated to fluorochromes. The principle of FACS is that a 
stream of single cells flow in a liquid medium channel past an excitation light source where 
the specific light scattering and fluorescent characteristics and wavelength for a specific cell 
type are measured. This light emission data is recorded by an optical and an electronic system 
which translates the light signals into digital information enabling the sorting of specific cell 
types of interest.  
For our studies, using monoclonal antibodies, we sorted different cell populations from bone 
marrow tissue, GALT, lymph node tissue and peripheral blood. Table 2 shows the different 
panels used in papers II-IV. 
Paper Compartment Cellular Population Sorting Strategy 
II 
Bone marrow HPCs Lin−/ CD34+ 
Lin =  
CD3, CD14, CD16, CD19, 
CD20, CD56 
Bone marrow HPCs Lin−/ CD34− 
Bone marrow Bone marrow cells Lin−/ CD4+ 
Bone marrow Bone marrow cells Lin+/ CD4+ 
Blood *Memory CD4+ T cells CD45RO+/ CD27+/- 
III 
Blood/GALT *TNA CD45RO
-
/ CD27
+
 
Blood/GALT *TCTM CD45RO
+
/ CD27
+
 
Blood/GALT *TEM CD45RO
+
/ CD27
-
 
Blood/GALT Myeloid cells CD45+/ CD3-/ CD4low 
IV 
Blood/GALT/Lymph node *TNA CD45RO
-
/ CD27
+
/ CCR7
+
/ CD57
-
 
Blood/Lymph node *TCM CD45RO
+
/ CD27
+
/ CCR7
+
 
Blood/Lymph node *TTM CD45RO
+
/ CD27
+
/ CCR7
-
 
Blood/Lymph node *TEM CD45RO
+
/ CD27
-
/ CCR7
-
 
Blood Myeloid cells CD45+/ CD3-/ CD14+ 
GALT *TCTM CD45RO
+
/ CD27
+
 
GALT *TEM CD45RO
+
/ CD27
-
 
GALT Myeloid cells CD45+/ CD3-/ CD13+ 
HPC, hematopoietic progenitor cells; GALT, gut-associated lymphoid tissue 
*T cells also include CD45
+
/ CD3
+
/ CD4
+
/ CD8
-
 
3.3.2 Single-Genome Sequencing (SGS) 
To analyze viral HIV-1 RNA from plasma collected before initiation of antiretroviral therapy 
and during therapy we used single-genome sequencing. This method developed by Dr. Sarah 
Palmer and co-workers at the NIH, has the advantage of detecting minor variants while 
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avoiding PCR errors such as resampling and PCR induced recombination [195]. Depending 
on the plasma volume or HIV-1 RNA level, plasma samples are either micro-centrifuged or 
ultracentrifuged to spin down and concentrate HIV-1 RNA. The viral RNA is then converted 
to cDNA using random primers, or in the case of low viral loads gene specific primers. 
Thereafter, the sample is serially diluted (1:3 to 1:729 in 5mM Tris-HCL) over a 96-well 
polymerase chain reaction (PCR) plate to ensure that each well contains one HIV-1 cDNA 
molecule. According to Poisson distribution, the serial dilution yielding amplified product in 
less than 30% of the wells contains one HIV-1 cDNA copy at least 80% of the time. 
Amplification was done using a nested PCR procedure with primers flanking the gag-pol 
region (p6 through nucleotides 1-900 of reverse transcriptase, 1.3 kb fragment, papers I-IV) 
or the env region (V1-V3, 0.8 kb fragment, paper IV). Generated PCR products were 
detected by gel electrophoresis and subsequently the viral DNA amplicons were sent for 
sequencing. 
3.3.3 Single-Proviral Sequencing (SPS) 
We used a method called single-proviral sequencing to quantify and genetically analyze the 
HIV-1 DNA integrants in cells isolated from peripheral blood, bone marrow tissue, gut-
associated lymphoid tissue, and lymphoid tissue [56]. Using FACS (see section Fluorescent 
activating cell sorting) a broad spectrum of cells were sorted into vials, lysed and amplified 
using nested PCR. According to the same procedure described for single-genome sequencing 
the cellular lysate was diluted to obtain PCR products derived from single HIV-1 DNA 
molecules.  
3.3.4 Quantitative Viral Outgrowth Assay (QVOA) 
The QVOA is a limiting dilution virus culture assay that is used to quantify and analyze 
replication-competent HIV-1. In paper I, the QVOA was used as a standard for comparison. 
Replication-competent HIV-1 was isolated from purified resting CD4
+
 T cells from 
peripheral blood. The purification of resting CD4
+
 T cells was carried out using a two-step 
magnetic bead depletion protocol. Briefly, five-fold serial dilutions of highly purified resting 
CD4
+
 T cells were stimulated with the mitogen phytohaemagglutinin (PHA) and a ten-fold 
excess of irradiated allogenic healthy donor PBMCs. The stimulation of PHA and PBMCs 
induces global T cell activation which reverses latency at least in a fraction of cells carrying 
integrated HIV-1 DNA. CD4
+
 healthy donor lymphoblasts were added to detect the released 
replication-competent virus. The HIV-1 virus replicates in the CD4
+
 lymphoblasts and after 
2-3 weeks of culture the virus is detected using an enzyme-linked immunosorbent assay 
(ELISA) for HIV-1 p24 antigen (please see paper I for more details). 
3.3.5 Droplet Digital PCR (ddPCR) 
A ddPCR procedure was used to measure HIV-1 DNA and 2-LTR circles in PBMCs and in 
resting CD4
+
+ T cells (paper I). Cellular DNA was extracted, ethanol precipitated and 
thereafter eluted to increase the concentration. The DNA concentration was measured using a 
spectrophotometer to ensure the desired concentration. The extracted DNA was heated and 
then digested by a restriction enzyme. Plasmids encompassing the entire viral genome 
(pNL4-3) or 2-LTR junction were used as standards. Two sets of primers were used: primers 
flanking the pol region (HXB2 positions 2536-2662) or the LTR (HXB2 positions 9585-51). 
The PCR reaction mixture was loaded in an emulsification device and droplets were formed. 
Thereafter, the content was transferred to 96-well plates and the DNA was amplified using 
PCR. After cycling, the droplets were analyzed. The number of template copies per unit 
volume µ was estimated from the number of positive events detected in the corresponding 
channel and the number of total accepted droplets by maximum likelihood. 
    
3.3.6 Alu PCR for integrated DNA 
Alu PCR was used to measure integrated HIV-1 DNA in PBMCs and in purified resting 
CD4
+
 T cells (paper I). The DNA was isolated from PBMCs and resting CD4
+
 T cells, 
diluted, and assayed in replicates for integrated HIV-1 proviruses. In the first round of 
amplification the Alu primer is paired with an HIV-1 gag primer and in the second round of 
amplification a sequence in the HIV-1 LTR is targeted. To estimate integrated HIV-1 
genomes the detection signal is compared to a standard curve that correlates cycle thresholds 
with integration standard copy number. 
3.3.7 Quantitative PCR (qPCR) 
qPCR was used to analyze HIV-1 RNA and DNA in rectal biopsy samples from 19 
participants (paper I). Using FACS (see section Fluorescent activating cell sorting), CD4+ T 
cells were extracted and enumerated. Results were expressed as copies of HIV-1 RNA 
measured by RT-qPCR or DNA measured by qPCR per CD4
+
 T cell. Primers and a probe 
from the LTR region were used for detection. Three replicate samples of 500 ng of RNA and 
DNA from each donor were assayed. External standards for HIV-1 RNA or DNA were 
included. 
3.3.8 Single-Copy Assay (SCA) 
The current lower-limit of detection for clinical assays varies between 20-50 copies of HIV-1 
RNA/mL. The SCA, developed by Dr. Sarah Palmer and co-workers, can quantify HIV-1 
RNA concentrations in plasma down to 0.3 copies HIV-1 RNA/mL (paper I) [123]. To 
control for recovery of HIV-1 each plasma sample, containing a starting volume of 7 mL, is 
spiked with a known amount of an internal control virus derived from an unrelated retrovirus, 
the replication competent avian sarcoma-leucosis retrovirus vector (RCAS). Using 
ultracentrifugation the virions are pelleted and the total RNA is extracted. HIV-1 RNA and 
RCAS RNA are then converted to cDNA and quantified by real-time PCR. By using a 
specific primer and probe set, HIV-1 RNA can be amplified from nearly 90% of those 
infected with HIV-1 subtype B. For each plasma sample, three independent reactions are run 
with HIV-1 gag-specific primers encompassing a highly conserved coding region in gag (79 
bp) and two with RCAS gag-specific primers. PCR products are detected using fluorescent 
probes. The quantity of HIV-1 RNA in the original plasma sample is then calculated from a 
standard curve generated for each assay using serial dilutions of in vitro transcripts of the 
same region of gag.  
3.4 PHYLOGENETIC ANALYSES 
3.4.1 Alignment 
Using single-proviral sequencing and single-genome sequencing approximately 30 single 
genome sequences were obtained from each cell type and plasma sample. The 1.3kb large 
fragments, constructed using four overlapping primers, were assembled using an in house 
Perl script. The 1.3 kb contigs were thereafter aligned into multiple alignments files using 
MAFFT version 6.0 (http://mafft.cbrc.jp/alignment/software/). To ensure high quality data 
sequences all low quality sequences were discarded both automatically and manually. Each 
sequence was required to have the following: 1) electropherograms with a mean quality score 
of Q20 (99% accuracy), 2) bidirectional sequence reads of at least 1.1kb, and 3) no more than 
one single-nucleotide polymorphism (SNP) (>1 SNPs indicates amplification of more than 
one cDNA template). In addition all contigs were carefully scanned by eye to detect 
suspicious base calls and gaps which were trimmed, edited and/or discarded when considered 
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necessary. Finally, to discover potential contamination or mislabeling, phylogenetic trees 
were constructed including all patient-derived sequences as well as several laboratory strains. 
3.4.2 Phylogenetic Inference 
Since G-A mutations (discussed in 2.3.1.1) can be misinterpreted as sequence evolution it is 
crucial to identify hypermutant sequences. Therefore, before constructing each phylogenetic 
tree the sequence alignments were scanned for hypermutants using the on-line tool 
“Hypermut” at the Los Alamos HIV database (www.hiv.lanl.gov) [196]. When using the 
“Hypermut” program all sequences with a p-value less than 0.05 are considered to be a 
hypermutanted and discarded. In paper III, alignments were inspected for recombination 
using Split Tree or the genetic algorithm for recombination detection (GARD). The identified 
recombinants were divided into non-recombinant fragments and analyses were conducted on 
both full-length sequences and non-recombinant fragments. Phylogenetic trees were 
constructed using Maximum Likelihood in MEGA 5.0 and 5.1 [197]. The evolutionary model 
best fitting the dataset was selected using the on-line tool “FindModel” at Los Alamos HIV 
database [198]. Statistical branch support of the tree structure was obtained by 100 (paper II) 
and 1000 (papers III and IV) bootstrap replicates. In paper II, pNL-43 was chosen as the 
outgroup whereas in papers III and IV, where sequences sampled from more than one time 
point were included, no outgroup was included as it might be wrongly interpreted as the root 
of the tree.  
3.4.3 Measurements of Diversity and Evolution 
In paper II, average pairwise distance was used to assess the genetic HIV-1 diversity 
between the sequences for each patient. This was calculated using the p-distance model in 
MEGA 5.0. 
Compartmentalization analyses, both tree-based and distance-based, were conducted in 
papers III and IV to assess the degree of compartmentalization between sequences derived 
from different cell subsets and/or from different time points. [199]. The Simmonds 
association index (AI; tree-based) evaluates the deviation from randomness in the position of 
sequences derived from different cell subsets and/or different time points on the phylogenetic 
tree. In order to evaluate the degree of compartmentalization the method considers the 
contribution of each internal node based on its depth and it evaluates the robustness of both 
the population structure and the shape of the phylogenetic tree by considering the bootstrap 
analysis as implemented. Nodes with sequences from different samples are given a grouping 
value of 1, while nodes with descendants from the same sample are given a grouping value of 
0. A phylogenetic tree showing a high degree of compartmentalization of sequences will 
mostly contain nodes with sequences from the same sample and will be given a lower 
grouping value compared to one where each descendant node contained mixed variants. To 
evaluate the significance of the observed values, compartmentalization has to be 
demonstrated by comparing the grouping values with the obtained values calculated for a 
control dataset that has the same phylogeny. For this method this is achieved by randomly 
reassigning the sequence grouping labels in the dataset, while still retaining the relative 
numbers of sequences from each compartment and the tree structure [199, 200]. For papers 
III and IV, AI statistical support was obtained using 1000 bootstrap-resample replicates of 
the sequences, each with 10 sample label reassignments. Bootstrap values above 0.95 were 
considered significant.  
Wright’s measure of population subdivision (FST; distance-based) uses nucleotide distances 
to evaluate the degree of compartmentalization. The method compares the mean pairwise 
genetic distances between two sequences derived from two different time points to the mean 
pairwise genetic distances between two sequences derived from the same time point. The 
    
distances were measured using a maximum likelihood approach (GTR nucleotide substitution 
model) and statistical significance was obtained by a permutation test (10,000 permutations) 
which randomly allocates the sequences into time points. P-values <0.05 were considered 
significant evidence for a genetic subdivision of sequences isolated at different time points. 
To further evaluate the degree of evolution during suppressive therapy, we also investigated 
the correlation of genetic divergence and time (paper III) between two time points (between 
pre-therapy samples and on-therapy samples as well as between two pre-therapy samples 
were analyzed). This analysis, which is based on the estimated phylogenetic tree, was 
evaluated using linear regression analysis (root-to-tip analysis as implemented in Path-O-
Gen) [201]. A strong correlation between genetic divergence and time implies that viral 
evolution has occurred between the viral sequences isolated at the different time points, 
thereby suggesting a model in which there are productive cycles of viral replication during 
treatment. 
As a final analysis of the dynamics of HIV-1 during suppressive therapy, we estimated the 
evolutionary rate (papers III and IV) using a “root to tip regression analysis”. The 
evolutionary rates (nucleotide substitutions per site per year) were estimated between pre-
therapy samples and on-therapy samples (papers III and IV) and between on-therapy 
samples collected 7-9 months apart (paper IV).  
For more in-depth explanation of the methods used to measure diversity and evolution, please 
see the methods section for each scientific paper. 
3.5 STATISTICAL ANALYSES 
We estimated the HIV-1 infection frequency in each cell type using a maximum likelihood 
statistical analysis. For further information concerning the statistical analyses used in papers 
I-IV please see the relevant sections for each scientific paper. 
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4 RESULTS AND DISCUSSION 
A major barrier to HIV-1 eradication is the establishment of latent HIV-1 reservoirs. To 
achieve an HIV-1 cure several critical steps are needed: 1) determining which cell types 
contain persistent HIV-1 during suppressive therapy; 2) determining which compartments 
contain these cells; and 3) determining how the persistent HIV-1 reservoir is maintained. 
Since many different methods are used to measure HIV-1 reservoirs we compared the 
different approaches for quantifying the reservoir in paper I. In papers II-IV we used unique 
and sensitive assays to analyze defined cell subsets from different tissues collected from eight 
participants on long-term suppressive therapy: five participants who initiated therapy during 
early/acute infection when the virus typically is homogeneous; and three participants who 
initiated therapy during chronic infection when the virus is more genetically diverse. These 
analyses allowed us to determine how HIV-1 is subdivided among different cells and tissues, 
how the timing of treatment initiation (during early/acute versus chronic infection) influences 
the size and diversity of the viral reservoir in these tissue sites and allowed us to estimate the 
relative contributions of viral replication and viral production. Furthermore, the longitudinal 
study of persistent HIV-1 reservoirs allowed us to investigate the effects of cellular 
proliferation, differentiation and expansion on the maintenance and genetic composition of 
HIV-1 populations within specific T cells (paper IV).  
4.1 COMPARATIVE ANALYSES OF MEASURES OF THE HIV-1 RESERVOIR 
Today there are several different assays used to study and measure the HIV-1 reservoir. In 
paper I we compared eleven different approaches for quantifying persistent HIV-1 in 
patients on cART. The study involved seven analytical approaches and four different kinds of 
tissue samples. In this study 30 well-characterized participants were included, 10 who 
initiated cART during acute/early infection and 20 who initiated cART during chronic 
infection. The goal of this study was to provide insights into how reservoirs should be 
evaluated in future clinical trials aimed at eradicating HIV-1 infection. 
Results from the different assays were compared to the QVOA, which is currently considered 
the most sensitive assay for quantifying replication competent virus [145, 147, 161]. When 
measuring HIV-1 DNA in unfractionated PBMCs and purified resting CD4
+
 T cells, using 
ddPCR, we detected HIV-1 DNA in 28/30 and 14/16 participants, in PBMCs and resting 
CD4
+
 T cells respectively. These ddPCR assays showed more than 100-fold higher mean 
infected cell frequency compared to the QVOA. One likely reason for these differences is that 
the PCR assays detect defective viral genomes such as cells containing HIV DNA which was 
hypermutated by APOBEC3G [89, 90]. If the proportion of defective viral genomes was 
known then the PCR measurements might provide a reliable measure of the latent reservoir 
size. However, no correlation between the PCR assay and the QVOA was shown. Therefore, 
it may be possible that the defective HIV-1 genomes accumulate at different rates in different 
patients and thereby no correlation between the methods was found. We further evaluated a 
well-established Alu PCR assay which is specific for stably integrated viral genomes and 
ddPCR that does not distinguish integrated from unintegrated viral genomes [164]. The 
comparison of infection frequencies of cells between the Alu PCR and ddPCR showed 
similar results and significant correlation (r=0.85, P=0.0079). These assays correlated well 
due to the fact that unintegrated LTR circle forms of HIV-1 DNA only represent a small 
fraction of the total HIV-1 DNA and unintegrated HIV-1 DNA have a short half-life and are 
more prevalent in untreated patients [131, 132]. Despite this, the Alu PCR assay used to 
measure HIV-1 DNA in PBMC showed the best correlation with the QVOA, among the 
approaches evaluated (r=0.70, P=0.0008). The correlation was not as strong when Alu PCR 
and QVOA were performed on the same sample of resting CD4
+
 T cells, which may be due 
    
to the small number of samples and genomes available for analysis which affected the power 
to detect correlation.  
In addition, we measured HIV-1 DNA and RNA levels in rectal biopsy samples. The 
frequency of infected CD4
+
 T cells in the GALT were significantly higher compared to the 
frequencies of these infected cells in the blood. This is consistent with some earlier studies 
[157, 159], but does not agree with other studies (see paper IV) [125]. HIV-1 DNA levels in 
the GALT and blood showed a modest correlation. However, these HIV-1 DNA levels did 
not correlate with the QVOA. These results suggest that GALT may serve as an important 
HIV-1 reservoir and that it is necessary to examine multiple anatomical sites to properly 
measure the reservoir.  
Furthermore we used the SCA as a measure of persistent viremia [123]. HIV-1 RNA was 
detected in 20/30 study participants but the results from SCA did not correlate with the 
QVOA. If the activation of latently infected CD4
+
 T cells was the major source of residual 
viremia a correlation may be expected. However, recent studies show that HIV-1 RNA clones 
in plasma are rarely found in memory CD4
+
 T cells from blood, suggesting that residual 
viremia may come from an additional source [150]. This persistent viremia may come from 
infected cells not analyzed in this study such as cells located in lymph node follicles or cells 
from the central nervous system [202]. 
Overall, this study revealed several difficulties in measuring the reservoir. First of all, none of 
the currently available assays provide an accurate measurement of the reservoir size. Another 
important result is that the number of resting CD4
+
 T cells with defective proviruses may be, 
on average, 300-fold higher compared to the number of cells harboring replication-competent 
virus. Thereby, no PCR-based assay provides a precise and consistent indication of the 
amount of replication-competent HIV-1 DNA in resting CD4
+
 T cells. The great difference 
between the QVOA and the PCR-based methods may, in most part, be due to cells containing 
defective genomes, such as those genomes which are hypermutated or genomes with large 
deletions which would not result in replication-competent virus. A key finding from this 
study is that while PCR-based assays may overestimate the reservoir size, the QVOA 
provides only a minimal estimate of the frequency of cells harboring replication-competent 
virus.  
4.2 CELLULAR AND ANATOMICAL SITES OF PERSISTENT HIV-1  
In 2010 Carter and colleagues published a study showing that HIV-1 can infect and establish 
a latent cellular reservoir in multipotent progenitor cells. They detected HIV-1 in four out of 
nine patients analyzed with a frequency of one HIV-1 DNA molecule per 10,000 CD34
+
 
HPCs [63]. If HIV-1 has the ability to infect HPCs this would be yet another roadblock for an 
HIV-1 cure as these proliferative cells would generate an expanded set of progeny cells that 
contain and release genetically identical virus. In paper I we therefore aimed to answer the 
question whether HPCs function as a viral reservoir after several years of suppressive 
therapy. We sorted and analyzed different cell subsets isolated from bone marrow of eight 
participants enrolled in the Options Cohort who had been on successful cART for 3-12 years. 
From each subject 100,000-870,000 Lin
¯
/CD34
+
 were analyzed and none of these cells 
contained HIV-1 DNA. This result provides strong evidence that if Lin
¯
/CD34
+ 
HPCs are 
infected in patients on long-term cART, their infection frequency is very low. To further 
evaluate the viral content in more developed cells from the bone marrow we analyzed 
Lin
¯
/CD34
¯
, Lin
¯
/CD4
+
 and Lin
+
/CD4
+
. The number of Lin
¯
/CD34
¯ 
sorted was 580,000-
5,900 000 per subject, and we did not find a single HIV-1 DNA molecule. The absence of 
HIV-1 DNA in these cells indicate that their infection frequency is zero or very low. When 
analyzing Lin
¯
/CD4
+
 cells from bone marrow we found no HIV-1 DNA in any of the cells 
from participants who initiated therapy during acute/early infection (370 000-1 400 000 cells 
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per subject). However, we did detect HIV-1 DNA in the Lin
¯
/CD4
+ 
cells isolated from 
participants who initiated cART during chronic infection and we also found HIV-1 DNA in 
the Lin
+
/CD4
+ 
cells from both patient groups. The purity of Lin
¯
/CD4
+ 
cell sample was 72-
85%, therefore we cannot rule out the possibility of the sample containing a low number of 
Lin
+
/CD4
+
. Using phylogenetic analyses we compared the HIV-1 genetic populations in 
Lin
¯
/CD4
+ 
and Lin
+
/CD4
+ 
 from bone marrow to HIV-1 populations isolated from 
contemporaneous memory CD4
+
 T cells sorted from peripheral blood. The results showed 
genetic similarity between the HIV-1 populations in cells from bone marrow and peripheral 
blood implying an active cellular exchange between the compartments or that cells from 
peripheral blood were present in the bone marrow samples. The discrepancy between the 
Carter study and our study could be explained by different sorting strategies and differences 
in treatment periods. Overall the findings from paper II strongly suggest that HPCs are not a 
viral reservoir in patients on long-term suppressive therapy. 
To further characterize the HIV-1 reservoir we analyzed cells isolated from peripheral blood, 
GALT and lymph node tissue collected from the same eight participants studied in paper II. 
In papers III and IV we found that persistent HIV-1 infection takes place primarily in 
memory CD4
+
 T cells sorted from these compartments. By conducting single-HIV-1 DNA 
sequencing on specific numbers of each cellular subset, we could estimate the HIV-1 
integrant frequency of each cell type in each compartment. We found the HIV-1 integrant 
frequency of memory CD4
+
 T cells sorted from blood and GALT were similar. This was 
shown in both papers III and IV and is consistent with a study by Chomont et al. [125], but 
in disagreement with another study [159]. The differences between studies can be explained 
by the limited availability of cells from GALT and isolation from different anatomical sites of 
the GI tract. In further agreement with the study performed by Chomont and colleagues we 
found that HIV-1 integrant frequencies in naïve and memory T cells were similar in lymph 
node tissue specimens compared to peripheral blood (paper IV) [125]. We also calculated 
the contribution of each cell type to the overall reservoir. In paper III we found that the 
central and transitional memory CD4
+
 T cell (TCTM) population was the major T cell 
contributor to the HIV-1 reservoir in peripheral blood whereas effector memory T cells were 
the major T cell contributor to the HIV-1 reservoir in GALT during long-term cART. 
However, in paper IV the TTM population was found to be the major contributor and TCM the 
second largest contributor to the T cell HIV-1 reservoir in peripheral blood. The difference in 
the results between these studies can be explained by the different sorting strategies. For 
paper III the central and transitional CD4
+
 T cells were sorted as a combined cell type 
whereas in paper IV the two cell types were sorted separately. In addition to the memory 
CD4
+
 T cells, we also isolated and analyzed TNA and found that these cells also contained 
HIV-1 DNA, although at much lower frequencies.  
Myeloid cells have been proposed as a possible reservoir in patients on cART in several 
studies [152-154]. Therefore, we sorted and analyzed myeloid cells from peripheral blood 
and GALT in papers III and IV. In paper III we detected HIV-1 DNA in blood myeloid cell 
preparations from three of eight participants and in GALT myeloid cell preparations from 
four of the eight participants analyzed. In paper IV we analyzed 6-7 million myeloid cells 
from blood specimens and found an HIV-1 DNA integrant frequency of 0.00002% in two of 
the eight participants. From GALT specimens we detected HIV-1 DNA in myeloid cells in 
one of the eight participants. To investigate the possibility of contaminating T cells in the 
myeloid cell preparations we performed T cell receptor (TCR) sequencing. We identified 
TCRs in all myeloid samples where HIV-1 DNA had been detected, indicating the presence 
of low proportions of T cells. Therefore, we cannot rule out the possibility that the HIV-1 
DNA came from T cells. However, if myeloid cells contain HIV-1 DNA the frequency is 
extremely low and their importance as a latent reservoir may be limited.  
    
Consistent with earlier studies, results from papers II, III and IV, show that the frequency of 
HIV-1 DNA within cells from peripheral blood, GALT and lymph node is lower in 
participants who initiate cART during acute/early infection compared to participants who 
initiate cART during chronic infection [182, 184, 203]. These results provide evidence that 
the initiation of therapy during acute/early infection will influence the magnitude and 
composition of the viral reservoir. 
4.3 STABILITY AND MAINTENANCE OF HIV-1 RESERVOIR 
A critical issue is how the HIV-1 reservoir is maintained. Is viral replication completely 
stopped by cART? Is ongoing HIV-1 replication maintaining the reservoir or is it maintained 
in a different way? In papers III and IV we used different phylogenetic analyses to evaluate 
whether ongoing HIV-1 replication takes place during suppressive therapy. We analyzed the 
genetic composition of HIV-1 DNA sequences in cells isolated from peripheral blood, GALT 
and lymph node. We then compared these tissue-derived sequences to plasma-derived 
pretherapy RNA sequences and to contemporaneous plasma-derived RNA sequences 
collected after 4-12 years of cART. In paper IV we also conducted phylogenetic analyses of 
viral evolution on HIV-1 DNA sequences isolated from cells collected 7-9 months apart. If 
ongoing replication is maintaining the reservoir during cART one would expect to detect viral 
evolution between pre-therapy HIV-1 RNA sequences and the intracellular HIV-1 DNA 
sequences after long-term cART. In both studies we found that the phylogenetic distribution 
of on-therapy intracellular HIV-1 DNA sequences intermingled with HIV-1 RNA sequences 
isolated from plasma specimens obtained before therapy. The compartmentalization analysis, 
Wright’s measure of population subdivision (FST), in paper III showed evidence for genetic 
compartmentalization between sequences isolated before initiation of therapy and after 
several years of therapy in four of the eight patients. However, the corresponding AI values 
revealed that the degree of compartmentalization was low. This finding indicates that the 
HIV-1 reservoir during long-term cART is stable and not maintained by ongoing replication. 
Lack of substantial ongoing replication was also shown by an analysis investigating the 
correlation of genetic divergence and time between pre- and on-therapy sequences. This 
analysis showed a limited correlation in all patient samples. A lack of temporal correlation 
was also shown in paper IV when we conducted regression analysis on on-therapy sequences 
from cells collected 7-9 months apart. This was true for the gag-pol and the env region. 
Furthermore, when estimating the evolutionary rate of the HIV-1 sequences between the pre-
therapy and on-therapy time points, we found a very low evolutionary rate, indicating an 
extremely low but not zero, directional nucleotide change during the years on cART. A 
reason why the results do not show a total lack of viral evolution could be that we cannot 
exclude the occurrence of small bursts of viral replication, for instance during short periods of 
lower adherence, which would result in a few genetic changes. Another limitation in this 
study is that the pre-therapy samples for some patients were collected 12-180 days before the 
initiation of cART. The period when participants were not on therapy could allow for the 
accumulation of nucleotide substitutions. However, the phylogenetic analyses conducted in 
papers III and IV suggest that viral replication is not a major contributor to persistent HIV-1 
in patients receiving effective therapy.  
In paper IV we further evaluated the stability of the HIV-1 DNA integrant pool during 
effective long-term cART by comparing the HIV-1 integrant frequencies estimated in paper 
III to integrant frequencies in cells isolated from the same patients 7-9 months later. The 
comparison showed that the amount of HIV-1 DNA had changed by ≤4 fold between the two 
time points for all cells and compartments, indicating that the pool of naïve T cells and 
memory CD4
+
 T cells containing integrated DNA did not change dramatically over a period 
of 7-9 months. The detection of some fluctuation may reflect contractions and expansions of 
different cell types. 
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In paper IV we examined the distribution of identical HIV-1 intracellular env and gag-pol 
sequences isolated from participants who initiated therapy during chronic infection (paper 
IV). The results from this analysis showed that the virus populations in these participants 
contained up to 73% identical sequences and that only 3 of the variants involved in these 
expansions were found in pre-therapy plasma sequences. These findings indicate that the 
sequence expansions were most likely present due to cellular proliferation that occurred 
during cART rather than because they were deposited in multiple cells prior to therapy. An 
interesting finding is that TEM cells are more likely to contain identical HIV-1 sequences (2> 
genetically identical sequences) compared to TCM and TTM cells. The higher proportion of 
identical HIV-1 sequences found in TEM cells can be explained by the different rates of 
cellular proliferation. TEM cells have been shown to have the highest proliferation rate [125, 
204, 205] and therefore this cell type would have a greater likelihood of harboring clonal viral 
genomes. In paper II we identified the expansion of identical sequences from cells isolated 
from bone marrow and peripheral blood from one subject who initiated therapy during 
chronic infection. This clonal sequence contains a large deletion in the gag-pol viral gene 
region essentially eliminating the protease from this HIV-1 population, indicating that this 
viral population is not replication competent. This clone was also detected in paper III and 
IV. Results from the longitudinal study (paper IV) show that the sequence containing this 
deletion had increased from 82% to 92% among the TEM cells over a period of 8 months. This 
indicates that this deletion mutant expanded through cellular proliferation and/or clonal cell 
expansion with integrated virus and not through viral replication as the variant is unable to 
replicate without a functional protease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
5 CONCLUSIONS AND FUTURE PERSPECTIVES 
With the discovery of the latent reservoir and the recognition of its long-term stability, there 
has been a constant search for curative strategies to eliminate it. In order to measure the 
effectiveness of these new curative strategies, high throughput assays will be needed. In 
paper I we compare eleven different approaches for quantifying persistent HIV-1, and 
compare the effectiveness of each approach to the QVOA, which has been considered the 
gold standard. The QVOA assay has been very valuable for characterizing the latent reservoir 
in resting memory CD4
+
 T cells, but it is very laborious and costly. PCR-based assays, which 
are easier to perform and require fewer cells, unfortunately quantify both defective and 
replication-competent viral populations. Overall, the results from this study showed that 
PCR-based assays did not correlate well with the QVOA assay, indicating that no PCR-based 
assay provides a precise and consistent measurement of replication-competent HIV-1 in 
memory CD4
+
 T cells.  
The study also shows that there are major differences among the assays. The major difference 
was that infected cell frequencies determined by PCR-based methods are on average 300-fold 
higher than frequencies of replication-competent viral populations detected by the QVOA. 
However, it was recently shown that the QVOA underestimates the true replication-
competent reservoir [206]. When examining the HIV-1 sequences which did not give rise to 
viral outgrowth following cellular activation Ho and colleagues found that while many 
genomes were massively deleted or mutated approximately 12% appeared intact. Thus, the 
true size of the latent reservoir may be approximately 60-fold greater than estimated by the 
QVOA. Although each method alone may not be sufficient to measure the latent reservoir, 
together these models can be used to study many important characteristics of HIV-1 
reservoirs including location, size and persistence.  
In conclusion, the data presented in paper I indicate that no assay accurately measures the 
latent reservoir during trials of new curative strategies for HIV-1 infection. Therefore, the 
most reliable test of whether a patient is cured or not is to stop therapy. However, this must be 
done with careful planning and monitoring due to the fact that viral rebound can occur 
months and possibly years after remission and that drug resistance may develop if virus 
replication is initiated before drugs levels have dropped to zero. Nevertheless, there are many 
promising new approaches in development which will soon result in an assay for quantifying 
the latent reservoir. It is important that this assay is less-costly, sensitive, efficient, and 
provides an accurate measurement of the replication-competent latent reservoir. The TILDA 
assay is the most promising assay since it could be easily adapted for use in a clinical setting. 
Although it may overestimate the reservoir, this is more desirable than an assay giving an 
underestimation of the latent reservoir since that could lead to viral rebound.  
In papers II-IV we analyze different cell types containing intracellular HIV-1 DNA from 
unique tissue samples from a well-characterized cohort. We studied the genetic composition 
of HIV-1 DNA integrants and investigated how the HIV-1 DNA pool is maintained during 
effective cART. HIV-1 infection of HPCs in patients on long-term suppressive therapy, if it 
occurs, will greatly impede the possibility of a cure for HIV-1 infection. Using the newly 
developed single-proviral sequencing method we investigated whether HPCs contain HIV-1 
DNA during long-term cART. In this study we did not detect a single CD34
+ 
HPC containing 
HIV-1 DNA. The lack of infected HPCs provides strong evidence that if these cells are 
infected in patients on long-term cART, their frequency is very low. The more differentiated 
HIV-1 populations analyzed from bone marrow were phylogenetically similar to sequences 
derived from contemporaneous memory CD4
+
 T cells from blood. This result shows that 
HIV-1 populations from bone marrow are not unique, indicating an exchange of cells 
containing HIV-1 DNA between bone marrow and the peripheral blood. As bone marrow is 
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highly vascularized, we cannot rule out that the CD4
+
 cells containing HIV-1 DNA in bone 
marrow actually originated from blood. To formally prove that HPCs do not serve as a latent 
reservoir a much larger study is needed. However, it is difficult to find a large group of study 
participants that meet the required criteria (such as treatment period, well monitored, and 
fully suppressed patients etc.) and are willing to go through the painful procedure of bone 
marrow aspiration. The findings from paper II together with earlier studies strongly suggest 
that HPCs are not a viral reservoir in patients on long-term cART [151, 207]. This finding, 
weighs against conducting a larger study including more patients to more powerfully prove a 
negative. Questions will always remain: how many participants are needed to prove that 
HPCs are not infected? Can we be sure that the samples will not be contaminated with CD4
+ 
T cells? Also, a large bone marrow study would be very expensive, resources which would be 
more usefully devoted toward developing curative treatment strategies within the HIV 
research field. 
In papers III and IV we continued characterizing the integrated HIV-1 DNA pool by 
investigating the genetic composition of intracellular HIV-1 DNA in cells sorted from 
peripheral blood, GALT and lymph node tissue collected from the same 8 participants studied 
in paper II. Consistent with other studies, we found that the majority of HIV-1 DNA in all 
tissues (blood, GALT and lymph node) and both patient groups (acute/early and chronic) was 
located in the memory CD4
+
 T cells. In addition, we found that TNA cells also contained HIV-
1 DNA, although at a much lower frequency, indicating that this cell type may be a viral 
reservoir in patients on long-term suppressive therapy. Another cell type that may contribute 
to the latent reservoir is myeloid cells. In papers III and IV we analyzed myeloid cells from 
blood and GALT and found a few cells containing HIV-1 DNA. Since we found the presence 
of TCRs in all these myeloid cell lysates, we cannot rule out that the HIV-1 DNA found in 
these myeloid lysates was due to low-level T cell contamination. Our results indicate that if 
these cells are infected in blood and GALT the frequency is extremely low. However, since 
we have analyzed up to 7 million cells per patient, at two different time points, and as we 
detected TCRs in the few HIV-1 positive myeloid lysates, it is highly unlikely that myeloid 
cells are infected in patients on long-term suppressive therapy. 
In both studies we found that the frequency of cells containing HIV-1 in blood was similar to 
GALT. However, with relatively limited GALT cells available to us, our analysis was 
restricted to very low number of cells. When we analyzed lymph node tissue we found that 
the frequency of HIV-1 DNA was similar to the frequencies found in peripheral blood. Both 
these results indicate that memory cells circulate between these tissue compartments. Our 
longitudinal analysis of HIV-1 in specific T cell subsets collected 7-9 months apart showed 
that the levels of memory T cells containing intracellular HIV-1 DNA are relatively stable. 
Further studies are required to fully understand how the GALT and lymph node tissue serves 
as a reservoir. However, owing to the painful procedures required to obtain GALT samples, 
participants are understandably reluctant to provide such samples. Furthermore, due to the 
complex anatomical nature of GALT and lymph node tissues different areas in these tissues 
may have different viral burdens.  
A consistent result found in papers II-IV is that the participants who initiate therapy during 
early infection have a lower frequency of intracellular HIV-1 DNA implying that early 
initiation of therapy results in a smaller latent reservoir. Therefore, early initiation of therapy 
will most likely be beneficial for future research and efforts aimed at HIV-1 remission or 
cure. Therefore as shown in the study by Saez-Cirion and colleagues, very early initiation of 
therapy may hold the greatest promise as a curative strategy. For this strategy to work early 
and accessible testing is needed for diagnosis as well as early initiation of therapy, which is 
very difficult. However, this strategy will not benefit all newly infected individuals as many 
    
are unaware of their infection. Furthermore, this curative strategy of treatment during acute 
infection will not benefit chronically infected individuals.  
When cART was introduced it was possible to reduce plasma HIV-1 to below the detection 
limit and more recently researchers started to hope that it will be possible to achieve HIV-1 
remission and/or eradication. Despite successful treatment low-level viremia can be detected 
in most patients, indicating ongoing viral production. What is unclear is whether this viremia 
is from latently infected cells or from ongoing replication. Using phylogenetic analyses we 
studied viral evolution and genetic change in cells from participants on long-term suppressive 
cART. Results from our studies (papers III and IV) show very little evidence for viral 
evolution and genetic change. The minor evolutionary change shown by the evolutionary rate 
analyses can be explained by the accumulation of HIV-1 genomic nucleotide changes when 
participants were not fully suppressed. However, if low-level ongoing replication occurs, it is 
unknown whether this contributes to the latent viral reservoir. Overall these findings, which 
are in agreement with many earlier studies, strongly suggest that ongoing replication is not 
the major cause of viral persistence in these cells [46, 126, 127]. When cART is taken 
meticulously viral replication does not contribute to HIV-1 persistence. Rather, as examined 
in paper IV, the reservoir is primarily maintained by long-lived cells and the proliferation 
and expansion of CD4
+
 T cells. Here we evaluated the role that cellular proliferation plays in 
maintaining persistent HIV-1 during cART. In typical patients treated during chronic 
infection the viral population is genetically diverse and few sequences are identical. 
However, when studying the genetic composition of HIV-1 in the participants who initiated 
therapy during chronic infection we found that up to 73% were identical sequences. 
Interestingly, we found that these clonal sequences were more enriched in TEM which is a 
more differentiated cell type. These cells have the highest proliferation rate and therefore are 
more likely to contain clonal viral genomes [125, 204, 205]. This indicates that a small 
number of proliferating cells harboring HIV-1 DNA are contributing to the persistence of 
HIV-1 in TEM cells. The hypothesis that TEM cells are maintained through cellular 
proliferation was further proven in a subject who had many identical HIV-1 sequences in 
TEM. We found that this clonal species, which contained a 380bp deletion, essentially 
eliminating the protease gene, increased over time. This further indicates that HIV-1 
persistence during effective cART is driven in large part by the proliferation, differentiation 
and expansion of cell populations with HIV-1 infection and sustained and durable 
regenerative potential, rather than ongoing viral replication. These findings reveal that it will 
be crucial to not only block all infection of new cells, but also find strategies to block 
homeostasis of HIV-1 infected cells non-selectively and/or find strategies for purging the 
latent HIV-1 reservoirs at a greater efficiency than cellular proliferation. However, if the 
proliferating cells contain defective viral genomes that cannot be transcribed and produce 
proteins these should be invisible to the immune system and will therefore not be a concern 
for new rounds of infection. 
The development of cART for the treatment of HIV-1 remains one of the great triumphs of 
modern medicine. However, despite its success, this therapy has limitations. Effective therapy 
requires meticulous life-long adherence, which many HIV-infected patients find challenging. 
In addition, antiretroviral therapy is expensive and cannot be delivered sustainably to 
everyone in need. Importantly, since HIV-1 DNA persists as an integrated genome in long-
lived or slowly-dividing cellular reservoirs, current therapeutic approaches are not proven 
curative. Although several different cellular reservoirs have been suggested, it is likely that 
the relevant cells that need to be targeted for future aims at HIV-1 eradication are different T 
cell subsets, such as naïve T cells, memory T cells and potentially other T cells such as 
follicular helper T cells. A sterilizing cure may be impossible given that all cells containing 
HIV-1 must be eliminated. Nonetheless, there is great hope for an HIV/AIDS free generation 
within the near future. It is unlikely one specific therapeutic regimen will confront and defeat 
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the HIV epidemic. To reach the goal of an HIV/AIDS free generation will require not only 
curative therapies but universal access to testing services to make all HIV-1 infected 
individuals aware of their infection and ensure access to appropriate medical care and 
treatment.  
In light of many challenges aimed at HIV-1 remission there are several strategies that stand 
out as highly promising. These include shock and kill strategies which employ HDACi and 
immune checkpoint blocker strategies. Even if some cells containing HIV-1 are not 
eradicated, these strategies may eliminate a sufficient amount of infected cells to achieve 
HIV-1 remission.  
In conclusion, in the work presented in this thesis we show that there is still a need for high-
throughput assays that accurately measure the latent reservoir (paper I). In papers II-IV we 
analyze HIV-1 RNA and DNA from unique patient samples using well-validated and 
sensitive techniques, developed by our lab. The work has helped us to gain a fuller 
appreciation for the range of cells and tissues containing HIV-1 DNA in patients on long-
term cART and a better understanding as to how the pool of these HIV-1 DNA integrants is 
maintained in cell subsets from different tissues. Although our SPS assay is limited in its 
ability to distinguish replication-competent from replication-incompetent virus, these studies 
of the integrant HIV-1 DNA pool in patients on cART bring us several steps closer to 
understanding the HIV-1 reservoir. 
While a difficult challenge, finding the key to HIV-1 remission and/or eradication is well 
worth the effort! 
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